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PHOSPHORYLATION IMPAIRS DICER1 FUNCTION TO ACCELERATE AGING AND
TUMORIGENESIS IN VIVO

Neeraj K Aryal, B.S.
Advisor: Guillermina Lozano, Ph.D.
Abstract: Altered DICER1 protein levels are associated with developmental disorders,
infertility, macular degenerative blindness, aging, and cancer in humans. Recently, posttranslational regulation of Dicer1 via phosphorylation has been described in C. elegans.
Oscillation of Dicer1 phosphorylation to regulate its activity is essential for germ cell
development and embryogenesis in worms. These observations led us to posit that
Dicer1 protein levels and activity are under tight regulation for normal mammalian
homeostasis. To test whether phosphorylation of Dicer1 regulates its activity in
mammals, I generated phospho-mimetic knock-in mouse models by replacing Serines
1712 and 1836 with Aspartic acids individually or together (dual phosphorylation).
Dicer1 functions are impaired by phosphorylation at Ser1836, and further augmented by
Ser1712 phosphorylation. Constitutive Dicer1 phosphorylation at Ser1836 leads to
highly penetrant post-natal lethality, and accelerates aging and causes infertility in
survivors. Homozygosity of dual phosphorylated Dicer1 leads to a hypermetabolic
phenotype in MEFs and mice, while heterozygosity is sufficient to promote tumor
development and dissemination in two independent tumor models. I have identified a
phospho-Dicer1 specific miRNA signature that is strongly associated with metabolic and
oncogenic pathways. These data identify constitutive phosphorylation of Dicer1 as a
driver of pathologies in mammals, with the phenotypes in mice resembling the spectrum
of human diseases associated with dysregulated DICER1.
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CHAPTER 1

INTRODUCTION
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1.1 Dicer1 structure and functions
Dicer1 is an essential gene that is well conserved from yeast to humans (Bernstein
et al., 2003; Nicholson and Nicholson, 2002). In mice, it is 65Kbp in length and encodes
a 220KDa (1906 amino acids) RNase III family ribo-endonuclease that contains a
helicase domain, a domain of unknown function, a PAZ domain, catalytic RNase IIIa
and IIIb domains, and a double-stranded RNA binding domain (dsRBD) (Figure 1A) (Du
et al., 2008; Gan et al., 2006; Macrae et al., 2006). The helicase domain identifies
hairpins of pre-miRNA substrates; the PAZ domain acts as a ruler for specificity of
product length; the RNase III domains dimerize to carry out substrate cleavage; and the
dsRBD is required for substrate binding (Ma et al., 2012). The dsRBD has also been
identified to contain a non-canonical nuclear localization signal (Doyle et al., 2013).
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Figure 1: Dicer1 domains and sequence conservation A. Different domains of
Dicer1 and the sites of ERK-mediated phosphorylation in mice. B. Conservation of
phosphorylation sites in worm, fly, mouse and human.

3

Dicer1 activity mainly produces microRNAs (miRNAs), small interfering RNAs
(siRNAs) and piwi-interacting RNAs (piRNAs) (Burger and Gullerova, 2015). Micro
RNAs and siRNAs are both regulatory RNA molecules that can target specific mRNAs
for degradation, while piRNAs play essential roles during spermatogenesis. In humans,
miRNAs are the most abundant small RNA except in male germ cells where millions of
piRNAs are produced during spermatogenesis. Dicer1 processes pre-microRNAs (premiRNAs) into functional 21–23-nt miRNAs that play crucial roles in many biological
processes during development, homeostasis, and diseases (Kurzynska-Kokorniak et
al., 2015). Even though, Dicer1 is required for processing most miRNAs, Dicer1independent processing of miRNAs have recently been described (Cheloufi et al.,
2010). These observations are consistent with the findings in Dicer1-null cells where a
few miRNAs were unaffected, and a significant subset of miRNAs that were reduced but
present (Kim et al., 2016).
Recently, small RNA-independent nuclear functions of Dicer1 have been discovered
(Burger et al., 2017; Cheng et al., 2017; Roche et al., 2017; Roche et al., 2016; SkourtiStathaki et al., 2014; Swahari et al., 2016; White et al., 2014). These include
transcriptional gene silencing, RNA PolII release at transcriptional termination sites, premRNA processing, and DNA double stranded break repair. Interestingly, a recent study
has associated nuclear Dicer1 in cholangiocarcinoma (Cheng et al., 2017). Given its
diverse roles in many biological processes, mechanisms regulating Dicer1 function have
consequential impact on diseases and survival.
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1.2 Regulation of Dicer1
Multiple mechanisms for regulation of Dicer1 function and activity have been
proposed. For example, Dicer1 is thought to be regulated transcriptionally by SOX4,
MITF, TP53 and TP63 (Boominathan, 2010; Jafarnejad et al., 2013; Levy et al., 2010;
Su et al., 2010). However, our understanding of its transcriptional regulation remains
very nascent. Additionally, miRNA mediated control of Dicer1 transcript has been
proposed wherein miR-103/107, miR-192, and the let-7 miRNA family target the 3’UTR
of the Dicer1 (Kurzynska-Kokorniak et al., 2015). Thus, many factors tightly regulate the
levels of Dicer1 transcript. However, Dicer1 transcript levels are not always proportional
to its protein levels suggesting further regulation at the post-transcriptional level
(Wiesen and Tomasi, 2009).
Recent studies have shown that Dicer1 is also regulated post-translationally
(Burger et al., 2017; Drake et al., 2014; Gross et al., 2014). Extracellular signalRegulated Kinase (ERK)-dependent phosphorylation of C. elegans DCR1 at Ser1705
and Ser1833 is essential for oogenesis (Drake et al., 2014). The sites of
phosphorylation are well conserved across species (Ser1712 and Ser1836 in mice,
Ser1728 and Ser1852 in humans) and their phosphorylation is necessary and sufficient
for Dicer1 trans-localization from cytoplasm to nucleus in worms as well as in murine
and human cell lines. In worms, phosphorylation at Ser1705 and Ser1833 results in
inhibition of canonical function of DCR1 and negative regulation of ERK activation
(negative feedback), respectively. Thus, tuned regulation of phosphorylation and dephosphorylation is essential for oogenesis and embryogenesis. This discovery
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highlighted, for the first time, that Dicer1 function is under a tight context-dependent
control during development.
1.3 Dicer1 is an essential gene
Homozygous deletion of Dicer1 in mice results in early embryonic lethality, and
conditional deletion in all mouse tissue examined results in abnormalities including
malformation of the midbrain and cerebellum when deleted in neural crest, severe
hypothyroidism and shortened life span when deleted in the thyroid, impaired T cell
development and differentiation when deleted in T-cells, and heart failure and postnatal
lethality when deleted in heart (Bernstein et al., 2003; Buza-Vidas et al., 2012; Chen et
al., 2008; Frezzetti et al., 2011; Harris et al., 2006; Kim et al., 2010; Korhonen et al.,
2011; Li et al., 2012; Liu et al., 2010; Muljo et al., 2005; Swahari et al., 2016; Xu et al.,
2012). Studies with hypomorphic Dicer1 alleles show that reduced levels of Dicer1 can
lead to lethality (Morita et al., 2009; Otsuka et al., 2007; Yang et al., 2005). Mice with
<20% of wild type Dicer1 mRNA levels are embryonic lethal, but >20% of wild type
levels is sufficient for survival. Therefore, tight regulation of Dicer1 at DNA, RNA and
protein levels is essential to avoid consequential impact on development, disease, and
survival.
1.4 Dicer1 is a haplo-insufficient tumor suppressor
Aberrant DICER1 expression or function is associated with poor prognosis in various
human cancers (Khan et al., 2017). DICER1 syndrome is an inherited tumor
susceptibility syndrome defined by germline missense and truncating mutations in
DICER1 that increases the risk of a variety of cancers including pleuropulmonary
6

blastoma (PPB), ovarian cancer, cystic nephroma, and thyroid cancer. DICER1
truncations generally result in null alleles affecting both dosage and function. Missense
mutations (generally in RNase IIIb domain), on the other hand, do not affect DICER1
mRNA or protein levels, however, they result in selective downregulation of a specific
subset of microRNAs (Rakheja et al., 2014).
Somatic heterozygous DICER1 mutations, missense and truncating, are also
frequently observed in human cancers suggesting that it acts as a haplo-insufficient
tumor suppressor (Kurzynska-Kokorniak et al., 2015). Importantly, Dicer1
heterozygosity promotes tumorigenesis in mice, but its complete loss leads to tumor
regression consistent with the lack of homozygous deletion in human tumors (Arrate et
al., 2010; Kumar et al., 2009; Lambertz et al., 2010; Yoshikawa et al., 2013). Recently,
homozygous DICER1 mutations have been reported in many cancers, but the majority
of second-hits are missense mutations in the RNase IIIb domain resulting in selective
downregulation of 5p-miRNAs that are tumor-suppressive (Gurtan et al., 2012;
Kurzynska-Kokorniak et al., 2015; Rakheja et al., 2014). These studies suggest that the
selective pressure acting within tumors favor aberrant DICER1 expression or activity,
but not complete loss.
1.5 Dysregulated Dicer1 correlates with many human diseases
Aberrant DICER1 expression or function causes developmental defects and many
other pathogenesis in humans (Khan et al., 2017). In addition to cancer susceptibility,
DICER1 syndrome patients also display developmental defects like multi-nodular goiter,
macrocephaly, global developmental delay, lung cysts, and overgrowth suggesting a
7

diverse role of DICER1 in human physiology (Khan et al., 2017; Klein et al., 2014).
Reduced mRNA and protein levels of DICER1 have been associated with geographical
atrophy, an advanced form of age-related macular degeneration that causes blindness
in millions of individuals (Tarallo et al., 2012). This disease is independent of miRNA
pathway, and is driven by increased levels of Alu RNAs which are DICER1 targets.
In addition to changes at the DNA level, changes in DICER1 mRNA and protein level
have also been associated with many pathologies. Reduced DICER1 levels are
associated with Geographical Atrophy (an advanced form of age-related macular
degeneration that causes blindness in millions of individuals), azoospermia (resulting in
male infertility), and aging (Mori et al., 2012; Tarallo et al., 2012). Mouse studies with
hypomorphic Dicer1 alleles show that reduced levels of Dicer1 mRNA and protein lead
to lethality (Morita et al., 2009; Otsuka et al., 2007; Yang et al., 2005). These results
suggest that dysregulation of Dicer1 is a potent driver of human pathologies.
1.6 Rational and specific Aims
Extracellular signal-Regulated Kinase (ERK) dependent phosphorylation of
DCR1 at Serines 1705 and 1833 is essential during oogenesis in C. elegans (Drake et
al., 2014). These sites (Serines 1712 and 1842 in mice) are well conserved across
species and their phosphorylation is necessary and sufficient for Dicer1 translocalization from cytoplasm to nucleus in worms as well as murine and human cell lines
(Figure 1B). Phosphorylation at Ser1705 and Ser1833 results in inhibition of canonical
function of DCR-1 and negative regulation of ERK activation, respectively (Drake et al.,
2014). Precise regulation of phosphorylation and de-phosphorylation is essential for
8

oogenesis and embryogenesis in C. elegans. This discovery highlighted, for the first
time, a mechanism of post-transcriptional regulation of Dicer1 function in vivo. I
hypothesize that phosphorylation will impair Dicer1 function in mammals in vivo,
and constitutive phosphorylation of Dicer1 will lead to developmental defects and
pathogenesis.
To evaluate if phosphorylation mediated regulation of Dicer1 function is conserved in
mammals, and to understand the impact of deregulation of this process on development
and disease, I will generate and characterize three phospho-mimetic Dicer1 knock-in
mouse models. The specific aims of my research were:
1. To generate phospho-mimetic Dicer1 Knock-in mouse models and examine the
importance of phosphorylation on Dicer1 function in mammals.
a. Using traditional gene targeting strategy
b. Using CRISPR/Cas9 targeting method
2. Phenotypic characterization of the mice to determine the impact of constitutive
Dicer1 phosphorylation on mouse physiology.
a. Generate a cohort of heterozygous and homozygous mutant mice.
b. Test viability of homozygous mutants
c. Follow them for development of cancer or other malignancies.
d. Perform histopathological examination of all major tissues.
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e. Compare nuclear vs cytoplasmic localization of Dicer1 in various tissues.
f. Compare miRNA profile of mutant vs wild type cells and tissues.
3. To examine the role of phospho-Dicer1 in promoting tumorigenesis.
a. Introduce DicerS2D allele into KRasLA1/+ and p53-/+ driven tumor models.
b. Generate cohorts of mice and follow them for tumor development.
c. Compare tumor spectrum, metastasis and survival.

10

Chapter 2

Generation of phospho-mimetic Dicer1 mouse models

11

2.1 Introduction
Dicer1 function and activity needs to be tightly regulated because it plays essential roles
in many biological processes. Recently, phosphorylation mediated control of Dicer1
functions have been described in worms and mammalian cell lines (Drake et al., 2014).
However, there are no mammalian models to study whether phosphorylation regulates
Dicer1 function and activity in vivo. In this chapter, I have described the generation of
phospho-mimetic Dicer1 mouse models using traditional embryonic stem (ES) cell
targeting and CRISPR/Cas9 based targeting methods.
2.1.1 DNA construct mediated ES cell Targeting
This method utilizes DNA constructs with desired mutation(s) to target the endogenous
locus in the ES cells. Homologous recombination at the targeted site will result in
integration of the mutation(s). The construct contains a neomycin resistance gene with a
PGK promoter to allow selection. The advantages of this method include: it is a wellestablished system, millions of cells can be targeted at once, and drug based selection
can be used. The disadvantages include: it is time consuming, has high cost and low
efficiency. Using this method, I have successfully generated two mutant mouse models,
one with both Serines replaced with Aspartic acids (Dicer2SD) and the other with only
Serine 1836 replaced with Aspartic acid (DicerS1836D).
2.1.2 CRISPR/Cas9 based targeting of mouse zygot e
CRISPR/Cas system has revolutionized the field of genome-editing as it is easier,
faster, inexpensive, and more efficient than traditional methods. In a very short time, its
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application has become very diverse and widely used. The disadvantages of this
technology include limited zygotes that could be targeted, off-target effects, restriction of
sites that can be targeted (Proto-spacer Adjacent Motif site required), and bi-allelic
deletion can be lethal. I have used CRISPR/Cas9 system to replace Serine 1712 with
aspartic acid and generated DicerS1712D mutant mice. In addition, a Dicer deletion
mutant DicerS1712fsT (frame shift truncation at position 1712) and a non-phosphorylatable
mutant Dicer∆1712 (deletion of amino acid 1712) were also obtained. The possibility of
creating off-target mutations with unknown consequences is the biggest hindrance of
this technology. There have been many reports of high-frequency off-target mutations in
human and mouse cell-lines, but unwanted errors in mouse embryo editing has been
deemed as a rarity (Iyer V. etal, 2015, Nat Methods). Here, I have shown that high
frequency off-target mutation is a possibility.
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2.2 Methods
2.2.1 Dicer1 targeting construct design to replace Serines 1712 and 1836 with
Aspartic acids in endogenous loci
The construct was designed to generate a double phospho-mimetic mutant
(S1712D and S1836D in the same allele) with possibilities to get single mutants. The
construct contains a floxed neomycin-resistance gene (neoR) inserted into intron 24 of
Dicer1 with 5.9 Kbp 5’ homologous arm and 2.7 Kbp 3’ homologous arm (Figure 2). The
5’arm contains S1712D mutation (TCT –> GAT) while the 3’arm contains S1836D
mutation (TCT –> GAT). The 5’ and 3’ homologous arms were PCR amplified using a
mouse bacterial artificial chromosome (BAC) clone plasmid (GenomeCube, Genomic
clone RPCIB731H16238Q, Library: RPCI-23, Host: E. coli / DH10B, Vector: pBACe3.6).
The 5’arm primers (both forward and reverse) contained added Xho-I site and the 3’arm
primers contained added Not-I sites. Each arm was sequenced, and cloned into
pCR2.1-TOPO vectors. Serine-to-Aspartic acid mutations were introduced using Agilent
QuikChange II XL site directed mutagenesis kit (primers contained 30 base homology
on either side of the mutations). The 3’arm was cloned into pGL-II vector containing the
floxed neoR cDNA using Not-I restriction digest and ligation. The vector was
sequenced, and 5’arm was cloned in using Xho-I restriction digest and ligation.
The S1712D mutation on the 5’ arm divides the homologous region into 4.2 Kbp
outer region and 1.7 Kbp inner region (considering neoR as the center). Similarly, the
S1836D mutation) divides the 3’arm into 2.0 Kbp outer region and 0.7 Kbp inner region.
When homologous recombination (HR) occurs at the outer regions of both homologous
14

arms, both mutations will be introduced and a double mutant will be generated. On the
other hand, if HR occurs at the outer region of one homologous arm (mutation is
introduced) and inner region of the other homologous arm (mutation is not introduced),
single mutants will be generated.
2.2.2 ES cell targeting and chimera generation
The construct was completely sequenced and successfully electroporated into
G4 mouse ES cells (George et al., 2007). Neomycin-resistant clones were screened by
Southern blotting using 5’ and 3’ external probes. SpeI-digested genomic DNA was
used for Southern blot screening (Figure 2). Positive clones (single and double mutants)
were confirmed by PCR and sequencing of targeted region. Two lines each of correctly
targeted ES clones (S1836D and 2SD) were injected into blastocysts which were
implanted into pseudo-pregnant females to generate chimeras. Male chimeras were
crossed to C57BL/6N females for germline transmission of the mutant allele. Male
progenies, one each, carrying the mutant alleles (S1836D or 2SD) were crossed with
C57BL/6N female mice carrying Zp3-Cre transgene to remove the neomycin resistance
gene. Male progenies carrying the mutant alleles (without neoR) were crossed with wild
type C57BL/6N females for 2 more generations to reduce possible mutations acquired
during ES cell growth in culture.
2.2.3 CRISPR/Cas9 based gene targeting
A 43-base sequence (20 bases on either side of the targeted codon) was used to
score all possible target sites using the crispr.mit.edu tool. A site with high score and
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containing the mutagenesis site in the seed region of sgRNA was selected for targeting.
Six possible off-target sites with a PAM sequence were also selected for screening. The
template for sgRNA synthesis by in-vitro transcription was generated by annealing two
oligos. The sequence for the sgRNA template is below. The T7 promoter sequence is
underlined, and sgRNA target sites are in bold.
GAAATTAATACGACTCACTATAGACCCACGGCAGCATTCTCCGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGT
CGGTGCTTTT
5µg of both oligos were mixed in nuclease-free water, and boiled for 5-10
minutes and then cooled at room temperature for 2hrs to overnight. 200-400ng of the
template was used to synthesize sgRNAs using the MEGAshortscript Kit (Invitrogen
AM1354), sgRNAs were purified by acid phenol-chloroform extraction and ethanol
precipitation (Invitrogen), re-suspended in 70µl of RNase-free water and further purified
by using Biospin P30 chromatography columns (#732-6223, Biorad) as per
manufacturer’s protocol. A final injection solution containing 10ng/µl Cas9 mRNA
(PrecisionX hspCas9 SmartNuclease mRNA, System Biosciences), 7.5ng/µl of sgRNA,
and 20ng/ul of donor oligo was prepared in Tris-EDTA buffer (5mM Tris, 0.1mM EDTA).
The final solution was injected into the pronucleus of 200-250 C57Bl/6N zygotes. The
zygotes were then implanted into pseudo-pregnant mice (20-25 per animal). All
injections and implantations were done in the MD Anderson genetically engineered
mouse facility.
2.2.4 Selection and screening of off-target sites
16

List of all possible off-target sites were obtained from crispr.mit.edu site for both
sgRNAs. All sites with less than 3 mismatches were screened. The following criteria
were used to select additional sites for screening with a preference on intra-genic sites:
a. Sites should contain a PAM (NGG, where N is any base) sequence.
b. Sites with higher score are selected first.
c. Sites with fewer mismatches are given preference.
For selected sites, primers are designed to amplify a 1Kb region and PCR products are
sanger-sequenced.
Dicer1 OTS1 Fwd: GCTCAGTGGCTGGCATATATG
Dicer1 OTS1 Rev: CCCAACTGCAGCTCCTTTG
Dicer1 OTS2 Fwd: GCCGTGATTTGGGACAAAAAG
Dicer1 OTS2 Rev: CCCCATAGGTGGGTTTGTATC
Dicer1 OTS3 Fwd: CCCCCATAGCTGGTTCAAAC
Dicer1 OTS3 Rev: GGCAACAAGGGCAGATACATG
Dicer1 OTS4 Fwd: CCTCTAGGCCTGTGATCAGAATAG
Dicer1 OTS4 Rev: GGCGGGTTAATGACTCATACAG
Dicer1 OTS5 Fwd: GGCTGGACATAGTTGTCTGTTG
Dicer1 OTS5 Rev: GCTCCACCTGGCTTCATTATC
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Dicer1 OTS6 Fwd: GAGGACCGATGGTTGTGAAAAATC
Dicer1 OTS6 Rev: CCTGGCACCTAGGAGAATTTAG
2.2.5 Mouse breeding, maintenance, screening and genotyping
Mice were maintained in >90% C57BL/6N background. All mouse studies were
conducted in compliance with an Institutional Animal Care and Use Committee protocol.
Live mice were weaned at the age of three weeks, and ear biopsies were collected. The
tissues were digested by Lysis buffer (1X PCR buffer, 1% Triton X, 250µg/uL Proteinase
K) at 550C overnight, and heated at 950C for 15 minutes to denature Proteinase K. 2µL
of the lysed tissue extract was used for PCR reaction to amplify 1Kb region of the
targeted site. The PCR product is gel purified and sanger-sequenced to identify any
indels at the target site.
S1712D screening primer Fwd: GTGCCAGGGATGTAGAAGAC
S1712D screening primer Rev: GGGCTGCAGGAATTCGATATC
S1836D screening primer Fwd: CACGTGGTACCTTAAGATGCATG
S1836D screening primer Rev: GCGGGTGACTTGAACCTAAG
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2.3 Results
2.3.1 Traditional construct based ES cell targeting
I generated a targeting construct that was successfully electroporated into TC1
ES cells to target the endogenous Dicer1 locus and replace Serines 1712 and 1836 with
Aspartic acids either individually or together (Figure 2). Of the 148 ES clones screened,
9 ES cell clones were identified to have intended mutation(s) at the target site by using
southern blot (Figure 3). Sequencing of PCR amplified targeted region from the selected
9 clones revealed that five clones contained both S1712D and S1836D mutations (2SD
hereafter), while the remaining four clones contained only the S1836D mutation (Figure
3). An ES clone with only the S1712D mutation was not obtained. Two ES clones each
(for S1836D and 2SD) were successfully injected into blastocysts to generate chimeric
mice. Mice with both Serines replaced with Aspartic acids (Dicer2SD), and only Ser1836
replaced with Aspartic acid (DicerS1836D) were obtained via germline transmission.
Mutant male mice (one each) were successfully crossed with C57Bl/6N females
carrying a Zp3-Cre transgene to remove the neomycin resistance gene.
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Figure 2: Traditional ES Cell Targeting Method. A DNA construct containing both
mutations (S1712D and S1836D, marked by stars) was used to target the endogenous
Dicer1 locus in ES cells. “X” marks the possible recombination sites. Dicer2SD allele was
generated by recombination at X1 and X4, while DicerS1836D allele was generated by
recombination at X2 and X4. SpeI restriction sites and expected size of DNA fragments
are listed.
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Figure 3: Screening of ES cell clones using Southern blot and PCR based
sequencing A. Southern Blot using 5’-probe (see figure S1A) with 7.1Kb mutant
band and 10.3Kb wild type DNA fragment. 8Kb and 11Kb markers (from DNA ladder)
are shown. B. PCR based screening with one primer outside of targeted region and
the other primer in the neo-R. C. Chromatographs from sequenced PCR fragment
are shown.
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2.3.2 CRISPR/Cas9 based targeting
I targeted Dicer1 gene to introduce Ser1712D mutation by using sgRNA, spCas9
mRNA, and a donor oligo (Figure 4). The sgRNA had a quality score of 76 with 124 offtarget sites according to www.crispr.mit.edu site (Figure 5). There was one off-target
site with 3 mismatches followed by PAM in the entire genome. All other off-target sites
had at least 3 mutations without a PAM site or had more than 3 mutations with a PAM
site. A total of 38 mice were born, and genotyped during weaning.
I observed on-target efficiency of 40% (15/38 animals) with non-homologous end
joining (NHEJ) being the predominant repair mechanism and 5% animals (2/38) were
mosaic with an allele that had the intended S1712D mutation introduced by homologous
recombination (HR) (Figure 6). A mouse model with only Ser1712 replaced with aspartic
acid (DicerS1712D) was obtained via germline transmission. NHEJ mediated repair at the
target site also produced a deletion mutant (Dicer -) with frame shift truncation at
position 1712, and a S1712 deletion mutant (Dicer∆1712) with 3bp in-frame deletion of
codon 1712. (See Table1 for all Dicer1 alleles generated).
I screened six potential off-target sites in the two mice with intended S1712D
mutation, and notably identified mutations at a site with three mismatches in target
sequence (Figure 6). I sequenced this off-target site in all 38 mice generated. At this site
with mismatches at positions 1, 4, and 8 (where 1 is farthest from the PAM site), I
observed mutations in 29% (11/38) of mice. In 3 animals, mutations were present at the
off-target site but not at the on-target site. Also, bi-allelic mutations were observed in 2
mice. I also sequenced another site with 4 mismatches at positions 1, 2, 5, and 8
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followed by PAM, but did not find any mutations in any of the 38 mice. The two mice
with intended S1712D mutation were crossed with wild type C57Bl/6N mice and one
progeny each carrying the S1712D mutation but lacking the off-target mutation was
selected. As the two mice with S1712D mutation also carried Dicer – or Dicer∆1712 allele,
progeny carrying one of these alleles without the off-target mutation were also obtained.
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Figure 4: CRISPR/Cas9 based targeting A. Targeting Strategy to replace
Ser1712 with aspartic acid in the endogenous Dicer1 locus. B. Chromatographs
from sequenced PCR fragment of mouse tail biopsy.
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Figure 5: List of candidate off-target sites for Dicer1 sgRNA per crispr.mit.edu.
Details of candidate off-target sites including sequence, loci, and mismatches are
listed.
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Figure 6: On- and off-target changes observed for all 38 mice born from
CRISPR/Cas9 targeted embryos. a. Allelic description for all mice at both on- and
off-target sites. *, mosaic at on-target site; #, mosaic at off-target site; WT, wild-type;
NHEJ, non-homologous end-joining; HR, homologous recombination. b. List of all
mutations observed at an off-target site with three mismatches. Off-target site is in
blue, mismatches are bolded and underlined, PAM is in green, deletions are
highlighted as X in red, and insertions are in red letters.
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2.4 Conclusions
In this chapter, I have described how the three phospho-mimetic Dicer1 mouse
models and two additional Dicer1 alleles were generated. Using the traditional ES cell
targeting strategy, I was able to generate a mouse model with Serine 1836 replaced
with aspartic acid (DicerS1836D) and a dual phospho-mimetic Dicer2SD mouse model with
both Serine1712 and Serine1838 replaced with aspartic acids. By using the
CRISPR/Cas9 based gene targeting on mouse zygotes, I was able to generate a mouse
model with only Serine 1712 replaced with aspartic acid (DicerS1712D). Additionally, a
mouse model with only Serine 1712 deleted (Dicer∆1712) due to a 3bp in-frame deletion,
and a Dicer1-null mutant (Dicer -) with frame shift truncation at position 1712 were also
generated.
I also report high frequency mutations at an off-target site with three mismatches
providing evidence that high-frequency off-target mutations is a possibility while using
CRISPR/Cas system to edit genes in mammalian embryos. Our data is consistent with
previous observations that this system is more tolerant when mismatches are away
from the seed region (defined as the eight bases in the target site closest to PAM).
In the following chapters, I will perform detailed phenotypic characterization of
mutant mice, and provide molecular insights underlying the phenotypes.
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Chapter 3

Dicer2SD/2SD and DicerS1836D/S1836D mice are partially post-natal lethal, small, and
infertile
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3.1 Introduction
Dicer1 is an essential gene for embryonic development, and homozygous
deletion results in embryonic lethality at E7.5 in mice (Bernstein et al., 2003).
Conditional deletion of Dicer1 in every mouse tissue examined results in abnormalities
and early lethality (Bernstein et al., 2003; Buza-Vidas et al., 2012; Chen et al., 2008;
Frezzetti et al., 2011; Harris et al., 2006; Kim et al., 2010; Korhonen et al., 2011; Li et
al., 2012; Liu et al., 2010; Muljo et al., 2005; Swahari et al., 2016; Xu et al., 2012).
Previous mouse studies with hypomorphic Dicer1 alleles have suggested that very low
levels of Dicer1 activity also results in embryonic lethality (Otsuka et al., 2007; Yang et
al., 2005). As phosphorylation of Dicer1 partially inhibits its function in C. elegans, I
examined the biological significance of phosphorylation-mediated regulation of Dicer1
function in mammals by generating three phospho-mimetic Dicer1 knock-in mouse
models. I have addressed three important questions in this chapter:
1. Does homozygous phospho-mimetic Dicer1 mutations lead to embryonic lethality in
mice?
2. If homozygous mutants are viable, are the mutant alleles functionally competent or
hypomorphic.
3. Finally, do the mutants display any developmental or fertility defects?
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3.2 Methods
Homozygous Viability Test
For each mutant allele, heterozygous mice were inbred and the progeny were
genotyped at weaning. From five Dicer+/S1712D mating pairs, ten litters with a total of 85
progeny were genotyped at weaning. From four Dicer+/∆1712 mating pairs, eight litters
with a total of 68 progeny were genotyped at weaning. From three Dicer+/− mating pairs,
five litters with a total of 28 progeny were genotyped at weaning. From seven
Dicer+/S1836D mating pairs, fourteen litters with a total of 103 progeny were genotyped at
weaning. From ten Dicer+/2SD mating pairs, eighteen litters with a total of 115 progeny
were genotyped at weaning.
E18.5 embryo Dissection
As previously described (Behringer 2013), heterozygous animals were mated
with each other, and plugs were examined every morning. Females positive for plug
(E0.5) were euthanized 18 days (E18.5) from that date. Uteri were dissected, and each
conceptus is separated and dissected. Embryos were weighed, and tail biopsies were
collected and genotyped.
Weight measurements
Weaned wild type (12 males and 12 females), DicerS1836D/S1836D (12 males and 9
females), and Dicer2SD/2SD (10 males and 11 females) were weighed (to a tenth of a
gram) every week beginning at four weeks after birth by using an electronic scale.
When a mutant mouse is euthanized, its littermate wild type mouse is also sacrificed. At
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least 3 mice were present at all time points (both males and females) from all
genotypes. An end point of ten months was selected because only two Dicer2SD/2SD
animals survived past this age.
Fertility Assay
8-12 week old homozygous mice (males and females) of all mutant alleles were
mated with C57Bl/6N wild type mice (8-16 weeks old). Mating pairs were monitored
daily and maintained until 1-2 litters were born. Litter size was counted and recorded at
the time of weaning. In the absence of any progeny, wild type animals were replaced
with younger (8-16 weeks old) wild type mice every two months for up to 6 months.
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3.3 Results
As Dicer1 is essential for embryonic development, we first evaluated the
homozygous viability of each of the mutant Dicer1 alleles generated. DicerS1712D/S1712D
and DicerΔ1712/Δ1712 mice were born and survived in the expected Mendelian ratios and
did not have any phenotype by 18 months of age (Table 1). Dicer −/− mutants were
embryonic lethal as previously reported (Bernstein, 2003). DicerS1836D/S1836D mutants
displayed partial lethality at weaning age (21 days post-partum). Of the 69 progeny from
the heterozygous crosses, 23 were wild type, 40 were heterozygous, and only 6 animals
(9%) were homozygous mutants, significantly different from the expected Mendelian
ratio of 1:2:1 (25%, 50%, and 25%) (p= 0.003). Dicer2SD/2SD mice, like the
DicerS1836D/S1836D mice, were also partially lethal at weaning age. Of the 115 progenies
from the heterozygous crosses, 34 were wild type, 73 were heterozygous, and only 8
animals (7%) were homozygous mutants, significantly different from the expected
Mendelian ratio of 1:2:1 (25%, 50%, and 25%) (p= 0.0001).
To investigate the timing of lethality in Dicer2SD/2SD mutants, we harvested and
genotyped E18.5 embryos from Dicer2SD/+ heterozygous crosses. Of the 42 embryos
examined, 10 were wild type, 22 were heterozygous, and 10 were homozygous
mutants, consistent with the expected Mendelian ratio of 1:2:1. We found that the
homozygous mutant embryos at E18.5 were alive (were breathing and moving after
dissection) suggesting that lethality was a post-natal event. This was further confirmed
by homozygous mutant genotype of dead pups found within four days after birth.
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Combined, these data suggest that homozygous phospho-mimetic mutation at Ser1836
is sufficient to impact post-natal viability.
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Table 1: Homozygous viability of mutant alleles
Allele

DicerS1712D

Dicer∆1712

Dicer −

DicerS1836D

Dicer2SD

Mutation
Ser
1712
Asp
Ser
1712
Del
Ser
1712
4aaSTOP
Ser
1836
Asp
Ser
1712,1836
Asp

Total
Pups

WT
Observed
(Expected)

Heterozygous Homozygous
Observed
Observed
(Expected)
(Expected)

85

17 (21)

48 (43)

20 (21)

0.440

68

21 (17)

35 (34)

12 (17)

0.300

28

8 (7)

20 (14)

0 (7)

0.008

103

28 (26)

64 (52)

11 (26)

0.003

115

34 (29)

73 (58)

8 (29)

<0.001

P
value
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3.3.2 Hypomorphic Assay
Previous mouse studies with hypomorphic Dicer1 alleles (reduced levels or
compromised function) have suggested that very low levels of Dicer1 activity also
results in embryonic lethality (Otsuka M, Immunity; Yang W JBC 2004) (Otsuka et al.,
2007; Yang et al., 2005). As many DicerS1836D/S1836D and Dicer2SD/2SD mutants were
postnatal lethal, we hypothesized that phosphorylation partially inactivates Dicer1
function. To test our hypothesis, we examined if phospho-mimetic Dicer1 is functionally
hypomorphic by introducing a null allele over each phospho-mimetic mutant
background. As previous mouse studies assessing Dicer1 function in mice have shown
that low levels of Dicer1 function are embryo-lethal, we expected that a hypomorphic
allele over a null allele would be lethal as well (Otsuka et al., 2007; Yang et al., 2005).
DicerS1712D/− and DicerΔ1712/− mutants were viable and normal, however, DicerS1836D/− and
Dicer2SD/− mice were non-viable (Table 2). These results demonstrate that
phosphorylation or deletion of Ser1712 has seemingly no impact on Dicer1 functions,
whereas phosphorylation at Ser1836 is sufficient to render Dicer1 functionally
hypomorphic as single allele (over a null allele) was insufficient for survival. Overall, our
results suggest that phosphorylation of Dicer1 at Ser1836 compromises its functions
with lethal consequences.
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Table 2: Hypomorphic Test of all mutant alleles

Dicer +/S1712D X Dicer +/−
Dicer +/+

Dicer +/−

Dicer +/S1712D

Dicer S1712D/−

P-value

6 (4.5)

3 (4.5)

5 (4.5)

4 (4.5)

0.77

Dicer +/+

Dicer +/−

Dicer +/∆1712

Dicer ∆1712/−

P-value

5 (4)

4 (4)

4 (4)

3 (4)

0.91

Dicer +/∆1712 X Dicer +/−

Dicer +/S1836D X Dicer +/−
Dicer +/+

Dicer +/−

Dicer +/S1836D

Dicer S1836D/−

P-value

8 (6)

10 (6)

6 (6)

0 (6)

0.02

Dicer +/+

Dicer +/−

Dicer +/2SD

Dicer 2SD/−

P-value

8 (5.5)

7 (5.5)

7 (5.5)

0 (5.5)

0.05

Dicer +/2SD X Dicer +/−
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3.3.3 Dicer2SD/2SD and DicerS1836D/S1836D mice are small
Dysregulated Dicer1 function has been associated with many developmental
diseases. As phosphorylation of Dicer1 at Ser1836 appears to be sufficient to
compromise its function, we suspected that mutant mice that survive post-natal lethality
may be prone to developmental defects. Therefore, we established a cohort of
DicerS1712D/S1712D, DicerΔ1712/Δ1712, DicerS1836D/S1836D and Dicer2SD/2SD mice, and followed
them for any developmental phenotypes. The Dicer2SD/2SD and DicerS1836D/S1836D mice
that survived early post-natal lethality were 35-50% smaller in size as compared with
their wild type littermates, and the growth retardation phenotype persisted throughout
the lifespan of these animals (Figure 7). The growth retardation phenotype was evident
in both male and female mutants, revealing no sex bias.
Even though, all neonatal homozygous Dicer2SD/2SD mutants were smaller than
their littermates, we could not distinguish between the animals that succumb to early
post-natal lethality from the eventual survivors.
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Figure 7: DicerS1836D/S1836D and Dicer2SD/2SD mice are small A. One week old (left)
and two week old (right) Dicer2SD/2SD (asterisk) and normal littermates. B. One to ten
month old wild type (WT), DicerS1836D/S1836D and Dicer2SD/2SD male (left, n=12 for all
genotypes) and female (right, n=12 for all genotypes) mice were weighed every
week. Average weight with standard deviation at various time points (in months) is
presented. Some mutant mice (DicerS1836D/S1836D and Dicer2SD/2SD) died before the
end-point of this study, and the number of animals in later time-points were smaller
than the numbers at the beginning of the experiment.
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3.3.4 Dicer2SD/2SD and DicerS1836D/S1836D mice are infertile
The growth defects in DicerS1836D/S1836D and Dicer2SD/2SD mice, combined with the
known association between reduced Dicer1 levels and infertility, made us wonder if
these mutant mice have any fertility defects. To test the ability of homozygous mutants
to breed, we housed male mutants with wild type females and vice versa.
DicerS1712D/S1712D and DicerΔ1712/Δ1712 mice were fertile, but DicerS1836D/S1836D and
Dicer2SD/2SD mice (both males and females) did not give rise to any progeny suggesting
that homozygous phospho-mimetic mutation at Ser1836 is sufficient to render the mice
infertile (Table 2). These results suggest that uncontrolled Dicer1 phosphorylation at
Serine 1836 is sufficient to drive early post-natal lethality, retard growth, and cause
infertility. Combined, these phenotypes strongly support a model that Dicer1 function
needs to be tightly regulated post-translationally for normal development, organismal
survival, and species conservation. We will focus on Dicer2SD/2SD mice from this point
forward as they display similar but enhanced phenotypes observed in DicerS1836D/S1836D
mutants.
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Table 3: Fertility Test

Male

Female

DicerS1712D/S1712D Wild Type

# Mating Pair

# Litters

Avg. Litter size

5

5

8.4

Wild Type

DicerS1712D/S1712D

5

5

7.8

Dicer∆1712/∆1712

Wild Type

3

3

8.7

Wild Type

Dicer∆1712/∆1712

4

4

8.0

11

0

0

DicerS1836D/S1836D Wild Type
Wild Type

DicerS1836D/S1836D

9

0

0

Dicer2SD/2SD

Wild Type

11

0

0

Wild Type

Dicer2SD/2SD

13

0

0
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3.4 Conclusions
In this chapter, I genetically tested whether constitutive phosphorylation of Dicer1
at Ser1712 and Ser1836, individually or combined, had any effect on the mouse
physiology. By inbreeding heterozygous mutants, I showed that constitutive
phosphorylation at Ser1836, alone or together with Ser1712, leads to postnatal lethality
suggesting that Dicer1 function is compromised. DicerS1836D and Dicer2SD alleles were
hypomorphic as DicerS1836D/- and Dicer2SD/- mice were not viable.
I also characterized the few DicerS1836D/S1836D and Dicer2SD/2SD mice that survive
postnatal lethality. These mice displayed growth retardation and infertility. As the
percentage of postnatal lethality and extent of growth retardation in Dicer2SD/2SD mice
was significantly higher than DicerS1836D/S1836D mutant, these results suggest that
phosphorylation at Ser1836 is consequential while phosphorylation at Ser1712
augments the phenotypes. Together, I have shown that phosphorylation at Ser1836 is
sufficient to drive developmental pathologies.
As the phenotypes of Dicer2SD/2SD mice were very similar but more pronounced
than DicerS1836D/S1836D mutant, only Dicer2SD/2SD mice were used for further experiments.
In the next chapter, I have performed a detailed phenotypic and histopathologic
characterization of Dicer2SD/2SD mice.
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CHAPTER 4

Dicer2SD/2SD mice exhibit accelerated aging phenotype
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4.1 Background
Reduced levels of Dicer1 is associated with developmental defects and aging in
mice and humans, and conditional Dicer1 alleles in mice have shown that it plays
essential role in all examined tissues (Buza-Vidas et al., 2012; Harris et al., 2006; Kim
et al., 2010; Korhonen et al., 2011; Li et al., 2012; Liu et al., 2010; Mori et al., 2012;
Morita et al., 2009; Xu et al., 2012; Yang et al., 2005). In the previous chapter, I showed
that DicerS1836D and Dicer2SD are functionally altered, and DicerS1836D/S1836D and
Dicer2SD/2SD mice display retarded growth and infertility which are frequently observed
phenotypes in mouse models of accelerated aging and human progeria patients
(Anderson, 2012; Harkema et al., 2016; Mori et al., 2012). Therefore, I suspected that
the homozygous mutant mice will have detrimental impact on different tissues resulting
in manifestation of additional developmental pathologies.
In this chapter, I have generated a cohort of wild type and Dicer2SD/2SD mice,
monitored them as they aged, and examined various tissues including the skeleton,
bone marrow, reproductive tissues, fat, skin, kidney, lung, liver, and heart at various
time points. I have also established a cohort of wild type and homozygous mutant mice
of all mutant alleles, and examined the effect of mutant alleles on median survival of the
mice.
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4.2 Methods
Micro-CT Scan
Micro-CT scans were performed at the small animal imaging facility of MD
Anderson Cancer Center. Detailed information can be accessed at
https://www.mdanderson.org/research/research-resources/core-facilities/small-animalimaging-facility/equipment/micro-ct_.html. Briefly, mice were anesthetized using
isoflurane, immobilized, and scanned using the Explore Locus RS pre-clinical in-vivo
scanner (GE Medical Systems) which is a cone-beam volume CT system that permits
live imaging of rodents. The X-ray source and CCD-based detector gantry is rotated
around the subject in roughly 1.0-degree increments. Geometric models were produced
by the system. MicroView software was used to create iso-surface with threshold of 700
(Th700) and 1000 (Th1000). Quantifications of bone mineral densities and total bone
fractions of spine were done at Th700. Kyphosis index was calculated as previously
described (Laws and Hoey, 2004).
Histopathology and H&E staining
Mice were euthanized by carbon dioxide exposure followed by cervical
dislocation. Full body necropsy was performed and harvested tissues were fixed in 10%
buffered formalin saline for 48-72 hours, followed by 100% ethanol for additional 48-72
hours. Tissues were submitted to the MD Anderson Core facility for paraffin-embedded
and sectioning. Five micrometer sections were stained by hematoxylin and eosin and
examined by light microscopy.
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Blood chemistry and CBC analysis
Mice were euthanized by carbon dioxide exposure followed by cervical
dislocation. Blood was collected from heart by puncturing it with a needle and syringe.
The samples were then submitted to MD Anderson Department of Veterinary Medicine
and Surgery for analysis.
Survival Curve
Mice were monitored every day, and the time of death was recorded. Moribund
animals were euthanized. Mice that had to be euthanized for non-moribund reasons
were excluded from the study.
Statistical analysis
Student's t-tests and Kaplan-Meier survival analyses were performed using Prism
6 software (GraphPad Software). P-values <0.05 were considered statistically
significant.
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4.3 Results
4.3.1 Dicer2SD/2SD mice exhibit kyphosis and osteoporosis
The most noticeable sign of accelerated aging in Dicer2SD/2SD mice was their
pronounced hunch posture starting at 6 months of age as compared with normal
posture in wild type littermates (Figure 8A). Micro-computerized tomography (Micro-CT)
scans of the 7-9 month old Dicer2SD/2SD and wild type mice confirmed severe kyphosis in
mutant mice as evident by statistically significant difference in the kyphosis index
relative to wild type mice (2.5 vs 3.7, p=0.02, Figures 8A-B). Kyphosis index is
calculated as the ratio of length of the spine (starting just below the neck and ending at
the junction of spine and tail bone) to the height of the spine (perpendicular line drawn
at the highest point of curvature) (Laws and Hoey, 2004). Micro-CT scan also revealed
severe osteoporosis in Dicer2SD/2SD mice with statistically significant reduction in bone
volume fraction (38% vs 65%, p=0.0003, Figure 8C) and bone mineral density (347
mg/cc vs 420 mg/cc, p=0.008, Figure 8D) in the spine of mutant mice as compared to
wild type. Histopathological examination of femoral-tibial bone sections showed the
bone marrow was infiltrated by adipocytes in mutant mice starting at 2 months of age,
and the adipocytes replaced most of the hematopoietic cells by 8 months (Figure 9A
and 9B). We also observed systemic bone loss throughout the skeleton of the mutant
mice (Figures 8A and 9A).
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Figure 8: Kyphosis and Osteoporosis A. Representative Micro-CT scans (isosurface threshold 1000) of wild type and Dicer2SD/2SD mouse skeletons. B. Kyphosis
index was quantified, averaged for wild type (n=4) and Dicer2SD/2SD mice (n=4), and
presented with standard deviation. C. Bone volume fraction (BVF) in the spine of
wild type (n=4) and Dicer2SD/2SD mice (n=4) was quantified, averaged, are presented
with standard deviation. D. Bone mineral density (BMD) of spine was quantified,
averaged for wild type (n=4) and Dicer2SD/2SD mice (n=4), and presented with
standard deviation.
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Figure 9: Bone Histopathology A. Representative H&E longitudinal section of
tibia from six month old wild type and Dicer2SD/2SD mice. Measurements are
shown for thickest and thinnest portion of the bone. B. Representative H&E
sections of femur-tibia from 2-8 month old Dicer2SD/2SD mice and 8 month old wild
type mouse.
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4.3.2 Reduced WBC and RBC
As hematopoietic compartments are housed in the bone marrow, we expected
the mutant animals to have compromised hematopoiesis. To understand the effects of
reduced bone marrow cellularity on hematopoiesis, we performed complete blood
counts (CBCs) and blood chemistry of the wild type and mutant mice at various time
points (2-9 months). Complete blood count analysis revealed no difference in platelet
count (p=0.89), 33% reduction in white blood cell count (4.18 vs 6.22 103/uL, p=0.01),
and 15% reduction in red blood cell count (8.6 vs 10.3 106/ul, p=0.007) in Dicer2SD/2SD
mice as compared with wild type (Figure 10). These results suggest that phosphomimetic Dicer1 dramatically impacts the skeletal integrity and hematopoietic cell
population of bone marrow, which may be the reason for an accelerated aging
phenotype.
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Figure 10: Complete Blood Cell Counts Complete blood counts of 2-8 month old
wild type (n=7) and Dicer2SD/2SD littermate mice (n=8). Average measurement with
standard deviation is shown. Each dot represents a mouse. Unpaired t-test analysis
was performed for all cell types; p=0.01 for WBC count, and p=0.007 for RBC count,
and p=0.89 for platelet count comparisons. WBC, white blood cell; RBC red blood
cell.
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4.3.3 Systemic Tissue Atrophy
The association of reduced Dicer1 level with tissue atrophy and degenerative
diseases like Geographical Atrophy, together with systemic bone loss in Dicer2SD/2SD
mice led us to suspect that the mutant mice may also be susceptible to systemic tissue
degeneration. Therefore, we examined multiple organs from Dicer2SD/2SD and wild type
mice histo-pathologically. Consistent with our previous observation of infertility in the
mutant mice, mutant testes sections from 2-7 month-old mice displayed tissue atrophy,
markedly reduced number of leydig cells and absence of mature spermatozoa (Figure
11). Similarly, the ovaries from homozygous mutant mice also displayed severe atrophy
as evident by vacuolated cells in the parenchyma, and the absence of mature oocytes
(Figure 11). The mutant skin epidermis was very thin with abnormal tissue architecture,
and had severely reduced layer of adipose tissue (Figure 11). Consistently, mutants
over 6 months of age were completely devoid of abdominal fat. The mutant tibia section
showed irregular thickening and thinning of the bone, and evidence of adipocytes
infiltrating the bone marrow (Figure 11). Additionally, other reproductive tissues
including the prostate, seminal vesicles, and uterus also displayed severe atrophy in the
mutants (data not shown). We also observed chronic cardiomyopathy, membranoproliferative glomerulonephritis, hepatocellular karyomegaly, lung bronchus-associated
lymphoid tissue (BALT) hyperplasia, and systemic inflammation in mutant mice.
Due to systemic disease affecting many organs in Dicer2SD/2SD mice, we
suspected that the mutant mice might have altered serum enzymes in circulation. As
expected, blood chemistry analysis revealed elevated levels of aspartate
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aminotransferase (729 vs 136 U/L), alanine aminotransferase (703 vs 63 U/L), and
alkaline phosphatase (202 vs 100 U/L) in mutant mice. All of these phenotypes present
in Dicer2SD/2SD mice were also evident in DicerS1836D/S1836D mice (data not shown). These
results suggest that phospho-mimetic Dicer1 drives systemic tissue atrophy with
detrimental pathologies such as infertility, osteoporosis, and cardiomyopathy; and
further supports our hypothesis that phosphorylation at Ser1836, or at both sites,
severely compromises Dicer1 functions.
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Figure 11: Systemic Tissue Atrophy Representative H&E sections of testes (20X),
ovaries (10X), skin (20X), and femur (5X) sections from eight month-old wild type
and Dicer2SD/2SD mice. Leydig cells (arrow) in testes section, ovarian parenchyma
(asterisk), adipocyte layer (rectangle) in skin, irregular bone thickness (arrow heads)
and adipocyte infiltration (white-filled circular cells, star) in the tibia sections are
marked.
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Figure 12: Dicer2SD/2SD eye phenotypes A. Representative image of eye phenotype
in a 4 month-old Dicer2SD/2SD mouse. B. Representative image of eye lesion in an 8
month-old Dicer2SD/2SD mouse and corresponding histological image of ulcerated
cornea.
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4.3.4 Dicer2SD/2SD mice exhibit reduced overall survival
The end result of accelerated aging is shortened lifespan, and we suspected that
these mutants may also have reduced survival. While all Dicer+/+ and DicerS1712D/S1712D
mice were alive by 18 months, Dicer2SD/2SD and DicerS1836D/S1836D mice had a median
survival of 236 days and 302 days, respectively (p=0.0001, Figure 13). The difference in
overall survival between DicerS1836D/S1836D and Dicer2SD/2SD mice was also significant
(p=0.02). Together, these results reveal that constitutive phosphorylation of Dicer1 at
ser1836, or at both sites, drives accelerated aging phenotypes including early post-natal
lethality, compromised weight gain, infertility, altered metabolism, kyphosis, systemic
tissue atrophy, and reduced median survival.
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Figure 13: Survival Curve Comparison Survival curve of wild type (n=57),
DicerS1712D/S1712D (n=15), DicerS1836D/S1836D (n=21) and Dicer2SD/2SD (n=21) mice
followed for 560 days. Vertical lines represent animals euthanized without morbidity.
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4.4 Conclusions
In this chapter, I have characterized Dicer2SD/2SD mice and detailed the impact of
impaired Dicer1 function on various tissues. Using micro-CT scan of wild type and
mutant skeletons, I demonstrated that mutant mice have kyphosis and osteoporosis.
Histopathological examination of tissues showed that mutants have atrophy in all
tissues examined. Overall survival analysis revealed that Dicer2SD/2SD mutant mice have
a significantly reduced median survival of 236 days as compared to wild type mice
which did not achieve median age by 600 days. Additionally, DicerS1836D/S1836D mice also
displayed a significantly reduced median survival of 302 days as compared with wild
type mice. Combined, I have shown that Dicer2SD/2SD mice display kyphosis,
osteoporosis, systemic tissue atrophy, and reduced lifespan which are all characteristic
of accelerated aging phenotype in mice (Gurkar 2015) (Gurkar and Niedernhofer, 2015;
Harkema et al., 2016). These results conclusively demonstrate that phospho-Dicer1
accelerates aging in mice.
The phenotypes due to constitutive phosphorylation at Ser1836, or at both sites,
have suggested that Dicer1 functions are compromised. In the next chapter, I have
examined the effect of phosphorylation on protein localization and miRNA processing
function.
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Chapter 5

Phospho-Dicer1 is nuclear localized and alters miRNA profile
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5.1 Introduction
Phosphorylation leads to nuclear localization of Dicer1 in C. elegans, and murine
and human cell lines. As the canonical miRNA-processing function of Dicer1 occurs in
the cytoplasm, translocation to the nucleus may have significant impact on its
cytoplasmic functions. I expected that phospho-mimetic mutation would also alter the
localization of Dicer1 in mice. In this chapter, I have examined the localization of all
phospho-mimetic mutant proteins in testes sections using immunofluorescence. I chose
the testes sections because it is one of the most affected organ in mutant mice. I have
also examined the localization of Dicer1 in kidney and liver sections from wild type and
Dicer2SD/2SD mice.
In the previous chapters, I have demonstrated that constitutive dual
phosphorylation of Dicer1 drives many pathologies suggesting that its functions are
altered. The primary function of Dicer1 is thought to be processing of pre-miRNAs into
mature miRNAs. I expected that phosphorylation will impair this canonical function of
Dicer1. In this chapter, I have examined the miRNA processing function of mutant
protein in MEFs and testes by small RNA sequencing and differential expression
analysis. I have also performed pathway analysis on differentially expressed miRNAs by
using DIANATOOLS software to determine which pathways are most affected.
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5.2 Methods
MEF preparation and cell culture
Dicer+/2SD heterozygous animals were inbred and plugs were examined every morning.
Females positive for plug (E0.5) were euthanized 13 days from that date (E13.5). Uteri
were dissected, and each conceptus is separated and placed in a 10cm plate with PBS
buffer. Each conceptus is dissected to recover the embryos. Fetal liver, head and limbs
(collected for genotyping) were removed from each embryo, and the remaining tissues
were chopped and treated with trypsin for 5-10 minutes at 37C. 5mL of DMEM media
(CORNING) supplemented with 10% FBS (GIBCO) and 1% penicillin/streptomycin
(Invitrogen) was added to each sample, and the cells were dissociated by pipetting up
and down. Cells were centrifuged, washed with PBS, re-suspended in 10mL media,
transferred to 10cm plates, and incubated at 37oC. Media was changed every 24 hours,
and the cells were harvested and re-plated (into 3-4 plates) when they reached
confluency. Early passage MEFs (P2, never frozen) were used RNA extraction and
RNAseq experiments.
Immuno-fluorescence staining
As previously described, tissues harvested from mice were fixed in 10% buffered
formalin saline and paraffin-embedded. Five micrometer unstained sections were
analyzed by immuno-fluorescence with respective antibodies. Total-Dicer1 antibody
(1:30, MABN461, EMD Millipore), phospho-Dicer specific antibody (1:100, generated by
Dr. Swathi Arur), and secondary antibody with fluorescent tags (1:500, Invitrogen). DAPI
was used for nuclear staining, and images were taken in Nikon 80i microscope.
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Small RNAseq and Pathway Analysis
RNA from Testes and MEFs were extracted and purified per manufacturer’s
protocol (Direct-zol RNA Miniprep plus, ZYMOL) and submitted to the M.D. Anderson
sequencing core facility. Barcoded libraries were prepared using the Illumina TruSeq
small RNA seq Kit. The libraries were sequenced on the NextSeq500. Quality
assessment of the Illumina raw reads was performed with FASTQC
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).
Nineteen hundred and fifteen mature miRNA sequences from the mouse genome
assembly GRCm38 were obtained from the miRBase and were used as reference for
subsequent short read mapping (Kozomara and Griffiths-Jones, 2014). Contaminating
adapter sequences were removed using the adapter scan function implemented in
SeqMan NGen® version 14 (DNASTAR, Inc, Madison, WI). Sequences with median
quality lower than phred = 30 were discarded from the analysis. Short read mapping to
reference mature miRNAs was also performed with SeqMan NGen® with the following
specifications: mer size (the minimum length of a mer, overlapping region of a fragment
read, in bases, required to be considered a match when assembling reads into contigs)
= 15; minimum match percentage (specifies the minimum percentage of matches in an
overlap that are required to join two sequences in a contig) = 95%; and minimum
aligned length (the minimum length of at least one aligned segment of a read after
trimming) = 18. Duplicate sequences were marked and combined.
Statistical analysis of mapped data from technical and biological replicates was
performed with ArrayStar® (DNASTAR Inc., Madison, WI). Briefly, normalization of
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mapped data was done using the RPM method, and fold change in miRNA abundance
between the wild type and mutant samples was calculated from log2 of total RPM
(Mortazavi et al., 2008). Significance of observed differences was determined with the
Student’s t-test and the Benjamini-Hochberg correction was employed for multiple
hypothesis testing; false discovery rate (FDR) was set at 0.05. Hierarchical clustering
was performed with the Euclidean distance.
Finally, all miRNAs with less than 10 reads/million in both groups (wild type and
mutant) were filtered out. Differentially expressed miRNAs with less than 2 fold
difference and confidence interval of <95% were also filtered out. From the final list,
pathway analysis on differentially expressed miRNAs was performed using
DIANATOOLS mirPath V.3 software. List of miRNAs were uploaded into the program,
and analysis was performed using three different target prediction tools (TarBase,
Targetscan and, microT-CDS).
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5.3 Results
5.3.1 Localization
To gain a molecular understanding of phosphorylation-mediated impairment in
Dicer1 functions, we first examined the localization of Dicer1 in mutant and wild type
testes sections. Immuno-fluorescence staining showed that wild type Dicer1 protein was
cytoplasmic in 97% of cells (both nuclear and cytoplasmic in 3% of cells), DicerS1712D
protein was cytoplasmic in 90% of cells (both nuclear and cytoplasmic in 10% of cells),
DicerS1836D was cytoplasmic in 70% of cells (both nuclear and cytoplasmic in 30% of
cells), while Dicer2SD was only nuclear in 100% of cells (Figures 14 and 15A). I also
confirmed nuclear localization of Dicer2SD protein in kidney and liver, where wild type
Dicer1 was cytoplasmic (Figure 15B). This result provided us with two insights. First,
phosphorylation at both sites is essential for efficient nuclear translocation of Dicer1
protein. Second, phospho-mimetic mutation at Ser1836 was sufficient to drive
phenotypes, even though, the protein was not nuclear in most cells. This suggests that
phosphorylation at Ser1836 is sufficient to impair Dicer1 functions, irrespective of its
subcellular localization.
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Figure 14: Localization of Dicer1 A. Immunofluorescence with anti-Dicer1
antibody on representative testes sections from wild type (WT), DicerS1712D/S1712D,
DicerS1836D/S1836D and Dicer2SD/2SD mice. Dicer1 is stained red while nuclei are
stained blue with DAPI. B. Percentage of spermatocytes (excluding spermatids
and sperm) with nuclear Dicer1 was calculated in the seminiferous tubules from
three mice of each genotype. Cells were binned as cytoplasmic or nuclear/both. 64

Figure 15: Dicer1 Localization in additional Tissues A. Representative image
showing how cells with nuclear Dicer1 was quantified in testes sections from
DicerS1712D/S1712D and DicerS1836D/S1836D mice. Only cells inside the two white circle
were considered. Cells with nuclear Dicer1 are marked by yellow circles. B.
Immuno-fluorescence (IF) with anti-Dicer1 antibody (red) on representative
kidney and liver sections from wild type (WT), and Dicer2SD/2SD mice.
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5.3.2 Small RNA sequencing analysis
As Dicer1 processes pre-miRNAs into mature miRNAs, we wondered if
phosphorylation interfered with this canonical function. We performed small RNAseq
analyses on MEFs and testes of wild type and Dicer2SD/2SD mice (four mutants and three
wild type samples in both sets). We found that subsets of miRNAs were downregulated
in both the testes and MEFs samples from Dicer2SD/2SD mice as compared with wild type
samples (Figure 16A). We observed that 359 miRNAs in MEFs and 368 miRNAs in
testes data sets were expressed at >10 reads per million (Figures 16 A-B). When we
compared the two datasets, we observed that 227 miRNAs were expressed in both.
Next, we applied a 95% confidence interval and greater than two-fold change as filters
for these data sets, and found 14% miRNAs (49/359) were downregulated and 4% of
miRNAs (14/359) were upregulated in the mutant MEFs. Similar criteria resulted in 14%
of miRNAs (52/368) that were downregulated and 5% of miRNAs (17/368) that were
upregulated in the mutant testes. In both MEFs and testes datasets, the average fold
difference in downregulated miRNAs was much greater (8-folds and 8.7-folds
respectively) than in upregulated miRNAs (3.1-folds and 2.4-folds respectively). As most
upregulated miRNAs had only modest change in comparison to downregulated
miRNAs, we focused on the downregulated miRNAs for further analysis.
Interestingly, of the 52 downregulated miRNAs in mutant testes, 39 were also
expressed in MEFs; and 41% (16/39) were downregulated in both tissues. Similarly, of
the 49 downregulated miRNAs in mutant MEFs, only 17 were also expressed in testes;
and 94% (16/17) were downregulated in both tissues (Figure 16B). This overlap strongly
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suggest that phospho-mimetic mutations in Dicer1 provides the specificity for robust
downregulation of a subset of miRNAs.
5.3.3 Pathway Analysis
Pathway analysis on the differentially downregulated miRNAs in MEFs using
DIANA TOOLS highlighted metabolic and cancer pathways as most affected (Table 4).
Pathway analysis on differentially downregulated miRNAs in testes also led to the
identification of the same metabolic and cancer pathways, further underscoring the
specificity of dysregulated processing of the affected miRNAs.
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Figure 16: miRNA Expression Analysis A. Differential expression of miRNAs in
Testes and MEFs from wild type (n=3 for both) and Dicer2SD/2SD mice (n=4 for both)
were analyzed. Green, red, and yellow dots represent downregulated, upregulated,
and unaffected miRNAs, respectively, in Dicer2SD/2SD samples as compared with wild
type samples. Blue lines represent 2-fold cutoff. B. Number of downregulated
miRNAs (>10 reads/million, and >2 folds difference), and overlap in mutant Testes
and MEFs. Overlapping miRNAs are listed.

68

Table 4: Pathway Analysis of Differentially Downregulated miRNAs in Mutant
MEFs Metabolic (Left) and Cancer-associated (Right) pathways are listed.
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5.4 Conclusions
In this chapter, I examined the localization of wild type and mutant Dicer1 in
testes sections by immunofluorescence. I revealed that wild type Dicer1 protein is
cytoplasmic in most cells, with 4% of cells having nuclear Dicer. Dicer protein was
nuclear in 10% of S1712D cells, 30% of S1836D cells, and 100% of 2SD cells. These
results provided us with two insights. First, phosphorylation at both sites is essential for
efficient nuclear translocation of Dicer1 protein. Second, phospho-mimetic mutation at
Ser1836 was sufficient to drive phenotypes, even though, the protein was not nuclear in
most cells. This suggests that phosphorylation at Ser1836 is sufficient to impair Dicer1
functions, irrespective of its subcellular localization. As Dicer1 processes pre-miRNAs
into mature miRNAs, we wonder if phosphorylation interferes with this canonical
function.
As aging is linked with altered metabolism and shares many features with cancer
pathways (Barzilai et al., 2012; Finkel et al., 2007), these results suggest that
downregulation of metabolic and cancer-associated miRNAs may be the driving force
behind the accelerated aging phenotypes in mutant mice. Therefore, I investigated
whether mutant mice have altered metabolism, and if the phospho-mimetic Dicer1 plays
a role in tumorigenesis in the next two chapters.
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Chapter 6

Dicer2SD/2SD mice and MEFs have increased respiration rates
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6.1 Introduction
Metabolism and growth are very closely linked, and alterations in metabolism can
have a direct impact on size and weight of an organism. In the last chapter, I discovered
that phosphorylation of Dicer1 leads to down regulation of metabolism associated
miRNAs. These observations led us to predict that Dicer2SD/2SD mice and MEFs will have
altered metabolism.
In this chapter, I tested my hypothesis by using Comprehensive Lab Animal
Monitoring System (CLAMS) test to measure activity, rates of oxygen consumption, CO2
release, respiration exchange rate, food and water intake, and weight gain/loss in wild
type and mutant mice. Four mutant and two wild type animals (2-3 month-old
littermates) were housed in individual metabolic cages and measurements were made
every minute for 24 hours. For MEFs, seven wild type and nine mutant lines were used
to assay oxygen consumption rate and extracellular acidification rate by using Seahorse
XFe96 extracellular flux analyzer.
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6.2 Methods
CLAMS Test
The CLAMS test was performed at Baylor college of Medicine. Their website
(https://www.bcm.edu/research/advanced-technology-core-labs/lab-listing/mousemetabolic-research-unit/instruments/clams) provides the details. Briefly, 6 mice (4
mutants and 2 wild type littermates) were housed in individual metabolic cages,
acclimatized for a few hours, and measurements were made every minute for 24 hours.
The calorimetry system monitored oxygen consumption rate and carbon dioxide
production rate. The free running wheels in each cage recorded the number of
revolutions and the time of day when the activity occurred. The CLAMS system also
monitored the amount of food consumed by the mouse, and the frequency and duration
of each meal. All animals were weighed at the beginning and end of the experiments.
MEF preparation and cell culture
As previously described in section 5.2, E13.5 embryos were dissected from
euthanized mice. Fetal liver, head and limbs were removed. The remaining tissues were
chopped and treated with trypsin for 5-10 minutes at 37oC. 5mL of DMEM media
supplemented with 10% FBS and penicillin/streptomycin was added to each sample,
and the cells were dissociated by pipetting up and down. Cells were centrifuged,
washed with PBS, re-suspended in 10mL media, transferred to 10cm plates, and
incubated at 37oC. Media was changed every 24 hours, and the cells were harvested
and re-plated (into 3-4 plates) when they reached confluency. Early passage (never
frozen) MEFs (P2–P3) were used for analysis.
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Seahorse Metabolic assays
As per manufacturer’s protocol (Seahorse Bioscience, XFe96 training manual),
P2 MEFs were trypsinized, counted, and re-suspended to a concentration of 200 cells/ul
in DMEM media supplemented with 10% FBS and penicillin/streptomycin. 4 mutant
MEFs and 3 wild type littermate MEFs were used. 80ul of each MEF samples (8
technical replicates) surrounded by blank wells (no cells) were plated into a 96-well
plate and incubated at 37oC overnight. Sensor cartridge was hydrated with XF calibrant
overnight at 37oC. Next day, the cells were washed and incubated with assay-specific
media (described in manual) for one hour at 37oC in a non-CO2 incubator. Sensor
cartridges was loaded into the machine for pre-calibration, and the plate with cells are
loaded when ready. Measurements (oxygen consumption rate and extra cellular
acidification rate) were done 3-5 times.
Statistical analysis
Student's t-tests analyses were performed using Prism 6 software (GraphPad
Software). P-values <0.05 were considered statistically significant.
6.3 Results
Our identification of downregulated miRNAs in Dicer2SD/2SD mutants as players in
metabolic pathways suggested that metabolism may be altered in these mice.
Additionally, alterations in metabolism have been shown to directly impact size and rate
of aging in organisms (White CR, PNAS, 2003). To determine whether metabolic
changes may be underlying the accelerated aging phenotypes of Dicer2SD/2SD mutants,
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we used the Comprehensive Lab Animal Monitoring System (CLAMS) test to measure
activity, rates of respiration, food and water intake, and weight gain/loss in 3-4 month
old mutant mice (before aging phenotypes manifest) and wild type littermates. We
observed that the mutant mice had a statistically significant 24% increase in average
oxygen consumption rate (OCR) as compared with wild type mice (52.6 vs 42.3
ml/kg/min, p=0.04, Figures 17A-B). Interestingly, this difference was more pronounced
during the light period when the mutant mice exhibited 38% higher OCR than wild type
mice (52.7 vs 38.1 ml/kg/min, p=0.02). Similar to the increase in respiration rates, the
mutant mice displayed a 50% increase in wheel activity than wild type mice (10,555 vs
7,057 rotations), and the difference was 2.5-fold during the light period (4,605 vs 1,853
rotations, Figure 17C). Together, these results indicate that Dicer2SD/2SD mice exhibit an
increased metabolic rate relative to wild type mice.
To compare metabolic changes at the cellular level, we assayed mouse
embryonic fibroblasts (MEFs) from mutant and wild type mice and measured their
glycolytic and mitochondrial respiration rates using the Seahorse Bioanalyzer.
Consistent with the results from the CLAMS test, Dicer2SD/2SD MEFs displayed a
statistically significant increase in oxygen consumption rate (OCR, p=0.02) and extracellular acidification rate (ECAR, p=0.04) as compared with wild type MEFs (Figures
18A-B). Mutant MEFs exhibited an OCR of 118.7 pmoles/min (34% higher) as
compared with 88.7 pmoles/min for wild type. Similarly, mutant MEFs exhibited ECAR
of 111.8 mpH/min (32% higher) as compared with 84.4 mpH/min for wild type. Overall,
these results provide strong evidence for the role of phosphorylated Dicer1 in metabolic
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pathways and suggest that increased metabolic rates may be the underlying
mechanism behind accelerated aging phenotypes of Dicer2SD/2SD mice.
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Figure 17: Higher Metabolism in Dicer2SD/2SD mice A. CLAMS test was used to
measure oxygen consumption rate (OCR) of wild type (n=2) and Dicer2SD/2SD mice
(n=4) from 10am to 9am. Rate of oxygen consumption (VO2) in mL/kg/min with
standard deviation is shown for every measurement. Vertical lines separate the light
period (6am -6pm) and dark period (6pm – 6am) during the experimental
measurements. In X-axis, 1 unit = 6 minutes from the beginning of measurement. B.
OCR rates were averaged and grouped into light period and dark periods. C.
CLAMS test was used to measure wheel activity of wild type (n=2) and Dicer2SD/2SD
mice (n=4). Measurements were combined and grouped into light period and dark
period. Each dot represents one mouse.
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Figure 14: Seahorse Assays

Figure 18: Higher Metabolism in Dicer2SD/2SD MEFs A. Seahorse mito stress test
assay was used to measure OCR of wild type (n=7) and Dicer2SD/2SD (n=9) mouse
embryonic fibroblasts (MEFs). Average measurements with standard deviation are
plotted. Student’s t-test was used, p=0.02. B. Seahorse glycolytic stress test assay
was used to measure extracellular acidification rates (ECAR) of wild type (n=7) and
Dicer2SD/2SD (n=9) MEFs. Average measurements with standard deviation are plotted.
Student’s t-test was used, p=0.04.
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6.4 Conclusions
In this chapter, I first measured the respiration rates and activity of wild type and mutant
animals using the CLAMS test. I show that Dicer2SD/2SD mice exhibit increased metabolic
rate and activity relative to wild type mice. Interestingly, these differences were more
pronounced during the light period when the mutant mice were resting. Consistent with
the results from the CLAMS test, Dicer2SD/2SD MEFs also displayed a statistically
significant increase in oxygen consumption rate (p=0.02) and extra-cellular acidification
rate (p=0.04) as compared with wild type MEFs. These results indicate that the
increased metabolic rates are likely the earliest defects presented in Dicer2SD/2SD mice
early during embryonic development, and likely influence the defects that manifest later.
Moreover, these increased rates of respiration and activity result in severely reduced
resting time of mutant mice that can be detrimental to overall health and may contribute
to early lethality. Overall, these results provide strong evidence for the role of
phosphorylated Dicer1 in metabolic pathways and suggest that increased metabolic
rates may be the underlying mechanism behind accelerated aging phenotypes of
Dicer2SD/2SD mice.
As the miRNAseq analysis suggested that metabolic and cancer associated
pathways are most affected, I examined the role of phospho-Dicer1 in tumor
development in the next chapter.
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Chapter 7

Phospho-Dicer1 promotes Tumorigenesis
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7.1 Introduction
Dicer1 acts as a haploinsufficient tumor suppressor, and loss of its function is
strongly associated with human tumor development (Kumar et al., 2009; Roche et al.,
2017). Phospho-mimetic Dicer2SD mutations also compromised Dicer1 function and
altered miRNAs associated with cancer pathways. In this chapter, I tested the ability of
phospho-mimetic Dicer1 to modulate tumor progression and tumor spectrum in two
independent cancer models. To separate the developmental phenotypes from cancerrelated lethality, I used heterozygous Dicer+/2SD mice.
I introduced a Dicer2SD allele into the KRas+/LA1 background. The KRasLA1 allele
consists of a duplicated exon1 containing the KRasG12D mutation, and every cell in the
mouse that accomplishes spontaneous recombination of the duplicated exon1 (10 -3 to
10-7 cells) will carry either a wild type allele or a mutant allele (Johnson et al., 2001).
This model gives rise to fully penetrant multifocal lung cancer starting at one week of
age and low frequency thymic lymphomas that varies by the background of the mouse. I
chose this tumor model because heterozygosity of the Dicer1 wild type allele
cooperates with KRasG12D lesion to drive lung cancer development in mice; and I
wondered if heterozygous Dicer2SD would do the same (Kumar et al., 2009).
The activated KRAS pathway cooperates with TP53 loss in many human tumors,
and TP53 regulates DICER1 transcription (Boominathan, 2010; Kumar et al., 2009). To
test whether phosphorylated Dicer1 is sufficient to promote tumorigenesis in the context
of p53 heterozygosity, I introduced a single Dicer2SD allele into p53+/− mice which
primarily develop osteosarcomas and lymphomas.
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7.2 Methods
Tumor Study
I crossed the heterozygous Dicer2SD allele into KRas+/LA1 (mixed background,
>95% C57Bl/6) tumor model, which specifically develops lung tumors with 100%
penetrance by one month (Johnson et al., 2001). A cohort containing 21 KRas+/LA1 mice
and 36 KRas+/LA1; Dicer+/2SD mice was generated in a mixed background (>90%
C57Bl/6N and <10% 129). The cohort was monitored for 400 days. Moribund animals
were euthanized, and their tissues were collected. Animals that were alive at 400 days
were sacrificed and their tissues were collected for pathology. Animals that were
euthanized due to non-tumor related issues (dermatitis, rectal prolapse) were not
included in the study. Tissues from 17 KRas+/LA1 mice and 24 KRas+/LA1; Dicer+/2SD mice
were collected for pathological examination. Tissue sections were prepared as the
tissues became available, and examined together when all samples were ready.
Similarly, I introduced the mutant Dicer2SD allele into the p53+/- tumor model. A cohort
containing 19 p53+/- mice and 32 p53+/-; Dicer+/2SD mice was generated. The cohort was
monitored for 540 days. Moribund animals were euthanized and tissues collected.
Animals that were alive at 540 days were sacrificed and tissues collected for pathology.
Animals that were euthanized due to non-tumor related issues (dermatitis, rectal
prolapse) were not included in the study. Tissues from 12 p53+/- mice and 21 p53+/-;
Dicer+/2SD mice were collected for pathological examination. Tissue sections were
prepared as the tissues became available, and examined together when all samples
were ready.
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Statistical analysis
Student's t-tests and Kaplan-Meier survival analyses were performed using Prism 6
software (GraphPad Software). P-values <0.05 were considered statistically significant.
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7.3 Results
7.3.1 Dicer+/2SD allele cooperates with KRas+/LA1 to drive Tumorigenesis
I expected that phosphorylation of wild type Dicer1 through KRas signaling axis
would tilt the balance towards increased phosphorylation of wild type Dicer1 and
promote tumorigenesis. KRas+/LA1; Dicer+/2SD mice developed a wide spectrum of tumors
and had a significantly reduced median survival of 353 days as compared with
KRas+/LA1 mice which did not achieve median age (p=0.03, Figures 19A-B). 94% (16/17)
of KRasLA1/+ mice developed lung adenomas/adenocarcinomas and one mouse was
tumor free. 88% (21/24) KRas+/LA1; Dicer+/2SD mice developed lung adenocarcinomas
and 58% (14/24) developed other tumors included 21% lymphomas (5/24), 25%
histiocytic sarcoma (6/24), and one each of hepatocellular carcinoma, mesothelioma,
endothelial cell tumor, hemangio-sarcoma and hemangioma (Table 5). The lymphomas
and histiocytic sarcomas were disseminated into multiple organs including lung, liver,
heart, kidney, spleen, and thymus in all affected mice. One KRas+/LA1; Dicer+/2SD mouse
also developed metastasis of the lung adenocarcinoma to the kidneys and heart. These
results indicate that phospho-mimetic Dicer1 cooperates with oncogenic KRas to
increase the tumor-susceptibility of multiple tissues resulting in a wide spectrum of
tumors, metastasis and reduced survival.
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Figure 19: Phospho-Dicer promotes tumorigenesis in KRas+/LA1model
A. Survival curves of KRasLA1/+ mice (n=21) and KRasLA1/+; Dicer2SD/+ mice (n=36)
followed for 400 days. Kaplan-Meier survival analysis was performed, p=0.03. B.
Representative H&E sections of Liver and Kidney showing lymphoma, histiocytic
sarcoma, and metastasis.
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Table 5: Tumor Spectrum in KRas+/LA1 mice and KRas+/LA1; Dicer+/2SD mice

Animals with dissemination of tumor cells into multiple organs are marked by *.
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7.3.2 Dicer+/2SD allele cooperates with p53+/− to drive Tumorigenesis
Similar to the KRas+/LA1 model, p53+/−; Dicer+/2SD mice exhibited a wide spectrum
of tumors and a reduced median survival of 497 days as compared with p53 +/− mice
which did not achieve median age (p=0.07, Figure 20 and Table 6). 71% of the p53+/−;
Dicer+/2SD mice developed tumors as compared with 25% in the p53+/− mice (Table 6). In
contrast to only osteosarcomas (16%) and lymphoma (8%) exhibited by p53+/− mice, the
spectrum of tumors in p53+/−; Dicer+/2SD mice included osteosarcomas (29%),
lymphomas (29%), histiocytic sarcomas, hemangio sarcoma, lung adenocarcinoma,
hepatocellular carcinoma, testicular carcinoma with metastases to multiple organs, and
some unidentified tumors (Table 6). 24% of p53+/−; Dicer+/2SD mice (5/24) displayed
multiple types of tumor including one mouse which developed osteosarcoma, lymphoma
and adenocarcinoma. Interestingly, lymphomas and histiocytic sarcoma were
disseminated into many organs as previously observed in KRas+/LA1; Dicer+/2SD mice. Of
note, none of the p53+/− mice developed multiple tumors or metastasis. Combined,
these data suggest that phospho-mimetic Dicer1 is a key driver of tumor progression
and dissemination in a context dependent manner.
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Figure 20: Phospho-Dicer promotes tumorigenesis in p53+/- model
A. Survival curve of p53+/- mice (n=19) and p53+/-; Dicer+/2SD mice (n=32) followed for
540 days. Kaplan-Meier survival analysis was performed, p=0.07. B. Tumor-free
survival of p53+/- mice (n=12) and p53+/-; Dicer+/2SD mice (n=21) followed for 540
days. Mice with tumors at the end-point were added to the curve. Kaplan-Meier
survival analysis was performed, p=0.03.
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Table 6: Tumor spectrum of P53+/- and P53+/-; Dicer+/2SD mice

Tumors of unknown origin are labelled as unspecified. Animals with dissemination of
tumor cells into multiple organs, based on pathological examination, are marked by *.
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7.4 Conclusions
In this chapter, I have genetically tested the ability of the Dicer2SD allele to drive
tumorigenesis in vivo in two independent tumor models. I have demonstrated that
phospho-mimetic Dicer1 cooperates with oncogenic KRas to increase the tumorsusceptibility of multiple tissues resulting in a wide spectrum of tumors, metastasis and
reduced survival. Similarly, phospho-mimetic Dicer1 also cooperates with p53
heterozygosity to drive a wide spectrum of tumors, metastasis and reduced survival.
Combined, these data suggest that phospho-mimetic Dicer1 is a key driver of tumor
progression and dissemination in a context dependent manner.
In the next chapter, I will summarize all the results, and discuss the clinical
implications and the significance of this study, and future directions.
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Chapter 8

Discussion
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8.1 Summary
In this study, I generated three phospho-mimetic Dicer1 mouse models and examined
the impact of uncontrolled phosphorylation on Dicer1 functions and organismal
wellbeing in vivo. I report four important findings. First, I have identified phosphorylation
as a critical regulator of Dicer1 function in mammals, and found that phosphorylation at
Ser1836 is sufficient to compromise its function and dramatically impact growth, fertility,
and survival in mice. Constitutive phosphorylation at Ser1712 and Ser1836 (referred to
as dual phosphorylation hereafter) further augment these phenotypes in mice.
Molecular analysis of dual phosphorylation mediated impact on Dicer1 function revealed
that not all Dicer1 substrates were affected equally, with subset of metabolic and
cancer-associated miRNAs being most affected. Second, constitutive phosphorylation
at both sites results in increased respiration rates and activity in mutant mice, consistent
with the specificity of altered miRNAs. Third, phospho-Dicer1 cooperates with other
oncogenic events to promote tumor progression and dissemination, as predicted by the
altered cancer-associated miRNAs. These observations highlight the specificity of the
altered Dicer1 functions. Fourth, dysregulation of Dicer1 phosphorylation can drive
many pathologies in mice that mimic pathologies in humans where DICER1 is mutated
or its levels are reduced, suggesting that regulation of Dicer1 function is critical for
normal development and constitutively phosphorylated Dicer1 is a pathological feature.
8.2 Physiological relevance of Dicer1 phosphorylation
Our results unveil that constitutive Dicer1 phosphorylation at Ser1712, or its deletion,
does not result in any significant phenotypes, suggesting that it does not impact Dicer1
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function on its own. We demonstrate that phospho-mimetic mutations at Ser1836 as
well as the dual phospho-mimetic mutations result in hypomorphic Dicer1 alleles rather
than null alleles. Relative to the Dicer1-null mice which display a fully penetrant
embryonic lethality at E7.5, many DicerS1836D/S1836D and Dicer2SD/2SD mice survive a
partial post-natal lethality (Bernstein et al., 2003). In addition, one copy of each allele
over a null allele is not viable, while Dicer1 heterozygous mice are viable and normal.
Physiologically, homozygous dual phospho-mimetic Dicer1 drives several pathologies in
mice such as increased respiration rates and activity, especially during the light period
when the wild type animals typically rest. Examining whether circadian rhythm is altered
in these mice would be an intriguing direction for the future
8.3 Post-translational regulation of Dicer1 Functions
Post-translational regulation of Dicer1 to control its activity is an emerging theme in
recent years. We first showed that ERK-mediated Dicer1 phosphorylation at Ser1705
and Ser1833 (corresponding to Ser1712 and Ser1836 in mice) inhibits DCR-1 function
in C. elegans (Drake et al., 2014). More recently, studies from human cultured cells
reveal that phosphorylation of DICER1 at Ser1728 and Ser1852 (corresponding to
Ser1712 and Ser1836 in mice) is required for a role in DNA damage response, while a
distinct phosphorylation at Ser1016 drives its nuclear localization (Burger et al., 2017).
Our results in mice highlights that phosphorylation at Ser1836 partially drives its
nuclear localization, and severely compromises its function, while dual phosphorylation
at Ser1712 and Ser1836 results in complete nuclear localization of Dicer1, and a
stronger phenotype than Ser1836 alone. In support of this model, we find that dual
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phosphorylation of Dicer1 leads to downregulation of a subset of miRNAs, and we
identify a phospho-Dicer1 specific miRNA signature. Our observations that dual
phosphorylation (a) leads to obligate nuclear localization of Dicer1 (b) increases the
severity of single Ser1836Asp associated phenotypes, leads us to propose that Dicer1
nuclear function together with the impaired miRNA processing exacerbates the strength
of the Dicer1 phenotypes. Future studies should help unveil the role of nuclear
phosphorylated Dicer1 in vivo.
We find that dual phosphorylation of Dicer1, affects a broader spectrum of tissues and
phenotypes than have been previously described for Dicer1 hypomorphic alleles.
Previous reports show that reduction of Dicer1 transcript to below 20%, causes severe
embryonic lethality similar to the null allele, while mutant mice with >20% Dicer1
transcript level, survive with minimal phenotypes. These data suggest that a threshold
of Dicer1 activity is necessary for survival. Our results provide new insight into Dicer1
function and show that phosphorylation offers a unique context for modulation Dicer1
function in distinct tissues and uncovers a broader range of Dicer1 function.
8.4 Phospho-Dicer1 drives oncogenesis
Germline and somatic Dicer1 mutations (missense, truncating, and deletion) have been
associated with human cancers, but the role of post-translationally modified Dicer1
remains unknown (Kurzynska-Kokorniak et al., 2015). We demonstrate, for the first
time, that phospho-Dicer1 cooperates with two distinct oncogenic lesions (KRas+/LA1 and
p53+/−) to drive a more diverse tumor spectrum and reduce survival. Importantly,
addition of phospho-Dicer1 heterozygosity in both tumor models resulted in
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development of high frequency lymphomas and histiocytic sarcomas that disseminated
into multiple organs. Additionally, a quarter of p53+/−; Dicer+/2SD mice and more than half
of KRas+/LA1; Dicer+/2SD mice developed two or more tumors. These results suggest that
phospho-Dicer1 not only plays a role in tumor development, but also promotes
development of multiple tumors and tumor dissemination.
In humans, recent reports document an association between nuclear DICER1 and
significantly reduced patient survival, increased tumor size, and lymph node metastasis
in cholangiocarcinoma (Cheng et al., 2017). Additionally, nuclear DICER1 was observed
in majority of human triple negative breast cancers, and breast cancer cell lines (Passon
et al., 2012). Of note, DICER1 expression was higher than normal tissues in
cholangiocarcinoma, similar to normal tissue in triple negative breast cancer, and lower
than normal cells in breast cancer cell lines. Based on our observations, we propose
that Dicer1 may be phosphorylated in all of these cases, and phosphorylation of
DICER1 is sufficient to promote tumorigenesis in humans.
8.5 Relevance of Dicer1 phosphorylation to human pathologies
Our discovery highlights a need to incorporate Dicer1 phosphorylation status as an
indicator of Dicer1 function and activity in human patients. Reduced levels of DICER1
has been associated with infertility in humans, and mouse studies have shown it is
essential for gametogenesis. Our study reveals uncontrolled Dicer1 phosphorylation as
a driver of infertility. It will be interesting to examine if infertility in humans is also
associated with dysregulated post-translational regulation of DICER1. Dicer1 syndrome
patients have early childhood mortality due to many cancers and other developmental
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defects. As homozygosity of phospho-mimetic Dicer1 drives early post-natal lethality in
mice, this mechanism may be an important consideration for such phenotypes in
humans. Reduced Dicer1 levels is associated with aging, and age-related degenerative
disease like GA. As phospho-mimetic Dicer1 mutants display robust accelerated aging
phenotypes, we suspect that dysregulation of this controlled post-translational
modification process is directly linked with aging. Dicer2SD/2SD mice have increased
respiration rates and activity, especially during the light period when the wild type
animals typically rest. It is interesting to speculate a role for DICER1 phosphorylation in
the pathogenesis of attention-deficit hyperactivity disorder (ADHD) because
hyperactivity is strongly associated with ADHD which affects millions of children
worldwide (Goldman et al., 1998). Together, we propose that dysregulation of Dicer1
phosphorylation is associated with multiple human pathologies, and pharmacological
intervention to control this process may have far reaching benefits.
Reversible protein phosphorylation is a wide-ranging form of regulation of proteins,
which in mammals exceed DNA and RNA level by thousands of fold; mammalian cells
have two copies of DNA, ~17 copies of mRNA and ~50,000 copies of proteins per gene
on average (Schwanhausser et al., 2011). Most studies on diseases focus on DNA level
mutations or gene expression changes, however our study suggests that this may not
be sufficient since post-translational protein modifications alter protein function without
alterations to the DNA or mRNA levels. Activities of proteins are usually measured by
levels of its candidate downstream targets or substrates, however, modifications
impacting only a subset of its targets or substrates can be missed by this approach. For
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example, if we had assayed the levels of only a few candidate miRNAs in the wild type
and mutant samples, we would have missed the differences in the affected miRNAs.
This study warrants the need to consider post-translational modification of proteins
alongside gene mutation and expression level during gene-to-disease associations.
8.6 Future Directions
Currently, genomic integrity and expression levels of Dicer1 are considered for many
human pathologies, but our discovery highlights a need to consider changes in the level
of Dicer1 phosphorylation. Together, I hypothesize that dysregulation of Dicer1
phosphorylation is associated with many human pathologies, and pharmacological
intervention to control this process may have far reaching benefits.
Constitutive dual phosphorylation of Dicer1 resulted in downregulation of subset
of metabolic and cancer-associated miRNAs, with a significant overlap between MEFs
and testes datasets suggesting that there is specificity of the affected miRNAs. It will be
interesting to know the characteristics of miRNAs that categorizes them into a specific
subset. Additionally, it might be informative to use phospho-Dicer1 specific miRNA
signature to stratify human tumors, especially the DICER1 syndrome tumors, and
investigate the differences in disease severity and median survival. Such analysis could
allow us to use phospho-Dicer1 as a therapeutic target to treat cancer and
developmental defects associated with aberrant Dicer1 activity.
Dual phosphorylated Dicer1 is localized in the nucleus in all tissues examined.
As more and more studies are revealing novel nuclear functions of Dicer1, I hypothesize
that nuclear functions of Dicer1 are also altered due to phosphorylation. This will be a
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very interesting future direction as my study, and few other published studies, suggest
that nuclear localization of Dicer1 is regulated by phosphorylation. As dual
phosphorylation alters canonical Dicer1 function, it would be informative to know if some
nuclear functions are enhanced. For example, Dicer1 plays important roles in
transcription and constitutive phosphorylation of Dicer1 may alter transcription of
specific genes. Dicer1 also plays important role in DNA damage response, and it will be
important to know whether constitutive phosphorylation enhances or inhibits the
response. Finally, nuclear Dicer is required to maintain stem cell quiescence which
could be altered due to phosphorylation.
Finally, understanding the impact of constitutive Dicer1 phosphorylation in a
tissue-specific manner would be very important. Fortunately, conditional wild type
Dicer1 allele has already been generated in mice. As heterozygous phospho-mimetic
mice are phenotypically normal, we can combine the phospho-mimetic allele with the
conditional allele, and use tissue-specific Cre to delete one allele only in that tissue. All
the cells in that mouse will have wild type protein except in the cells where Cre is active
resulting in production of only mutant proteins.
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Addendum:

Loss of Digestive Organ Expansion Factor (Diexf) reveals an essential role during
murine embryonic development that is independent of p53

This chapter is based upon previously published work in Oncotarget journal:
http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]
=22087&path[]=69974

The information and figures from this publication is being used with permission from
Oncotarget in accordance with the license used for all Oncotarget papers:
http://creativecommons.org/licenses/by/3.0/
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Introduction
The guardian of the genome, p53, is a tumor suppressor and transcription factor
that initiates cell cycle arrest and apoptosis in response to stress or insult and thereby
prevents damaged cells from proliferating. At the same time, p53 transcriptional activity
is tightly regulated in normal cells to prevent inappropriate activation of downstream
anti-proliferative or cell death programs (Lane, 1992). The two most prominent p53
inhibitors are Mdm2 and Mdm4 (Pant and Lozano, 2014) . Mouse models have
demonstrated that both Mdm2 and Mdm4 have essential roles in embryonic
development through inhibition of p53 activity. Homozygous loss of either gene is
embryonic lethal, a phenotype that is completely rescued by the concomitant deletion of
p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995; Parant et al., 2001).
Additionally, transgenic overexpression of either is sufficient to promote tumorigenesis
(Jones et al., 1998; Xiong et al., 2017). In human cancers, increased levels of MDM2
and MDM4 abrogate the need for p53 alterations (Wasylishen and Lozano, 2016).
However, many cancers retain wild type p53 without alterations in known p53 inhibitors
suggesting that novel mechanisms of pathway inhibition remain to be identified
(Wasylishen and Lozano, 2016).
Recently, digestive organ expansion factor (Diexf), was identified as a novel
inhibitor of p53 in zebrafish (Allton et al., 2009; Chen et al., 2005; Collavin et al., 2010;
Jain and Barton, 2009; Li et al., 2007; Liu et al., 2015). In addition, in zebrafish and
human cell lines, Def/Diexf recruits Calpain3 in the nucleolus to regulate p53 stability
through the Def-Capn3 pathway (Tao et al., 2013). DIEXF (Def in zebrafish) is an
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evolutionarily conserved gene that was first identified in zebrafish and shown to be
essential for expansion of digestive organs (Chen et al., 2005). It is located on
chromosome 1 in both human and mouse genomes coding for a 756 (772 in mouse)
amino acid protein. DIEXF does not have any known functional domains except a
glutamic acid repeat region in the amino-terminus which has been linked to RNAprocessing [16]. Recent works in yeast, Arabidopsis, and zebrafish has demonstrated
that Def is essential for pre-rRNA processing (Charette and Baserga, 2010; Harscoet et
al., 2010; Tao et al., 2017).
Loss of Def in zebrafish selectively up-regulates the expression of ∆113p53
isoform, transcribed from an alternative promoter in intron 4, in digestive organs
(Bourdon et al., 2005; Chen et al., 2005; Fujita et al., 2009). Def-null fish overexpress
∆113p53 which results in increased p53 target gene expression and induction of cell
cycle arrest in the digestive organs. This leads to under-expanded digestive organs and
lethality by 8-11 days after fertilization (Chen et al., 2005). Knock-down of both fulllength p53 and ∆113p53 levels partially rescues the mutant phenotype indicating that
Def acts as a negative regulator of p53 in zebrafish.
This study addresses the role of Diexf as a potential regulator of the p53 pathway
in mammals in vivo. I evaluated the function of Diexf in vivo by generating two
independent knockout alleles in the mouse using the CRISPR/Cas9 technology.
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Methods
Gene targeting strategy
The entire sequence of exon1 was used to score all possible target sites using
the crispr.mit.edu tool. The two sites with highest scores were selected for targeting.
Four and six possible off-target sites with a PAM sequence for sgRNA1 and sgRNA2
respectively were also selected for screening.
sgRNA(s) synthesis by in-vitro transcription
All in-vitro transcription kits use T7 polymerase which requires a G at the
transcription start site. For sgRNA1, N20 does not start with a G, and thus G (in
parenthesis below) is added to the sgRNA. The T7 promoter sequence is underlined,
and sgRNA target sites are in bold. Four random bases (GAAA) were added upstream
of T7 promoter sequence to provide anchorage for T7 polymerase binding.
sgRNA1 Forward Oligo:
GAAATTAATACGACTCACTATA(G)ATGGGCAAACGCCGGAACCGGTTTTAGAGCT
AGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCG
AGTCGGTGCTTTT
sgRNA2 Forward Oligo:
GAAATTAATACGACTCACTATAGCACCTCCGCGACTTCGGCGGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGT
CGGTGCTTTT

102

Oligos were suspended in nuclease free water to a final concentration of
500ng/µl. For each sgRNA, 5µg each of forward and reverse oligos (10µl each) were
mixed in 80µl nuclease-free water (100µl total volume) and boiled for 5-10 minutes and
then cooled at room temperature for 2hrs to overnight. 200-400ng of the prepared
templates were used to synthesize sgRNAs using the MEGAshortscript Kit (Invitrogen
AM1354) as per manufacturer’s protocol. sgRNAs were purified by acid phenolchloroform extraction and ethanol precipitation as per manufacturer’s protocol
(Invitrogen). sgRNAs were resuspended in 70µl of RNase-free water and further purified
by using Biospin P30 chromatography columns (#732-6223, Biorad) as per
manufacturer’s protocol to remove any remaining free nucleotides. The concentration
and quality of sgRNAs were determined by using Bio analyzer. If the concentration
measured by Nanodrop is significantly higher than Bio analyzer reading, it indicated free
nucleotide contamination. Column purification was repeated if necessary.
Zygote injection and implantation
A final injection solution containing 10ng/µl Cas9 mRNA (PrecisionX hspCas9
SmartNuclease mRNA, System Biosciences) and 7.5ng/µl of each sgRNA was
prepared in Tris-EDTA buffer (5mM Tris, 0.1mM EDTA). The final solution was injected
into the pronucleus of 200-250 zygotes. The zygotes were then implanted into pseudopregnant mice (20-25 per animal). All injections and implantations were done in the MD
Anderson genetically engineered mouse facility.
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Mouse breeding, maintenance, screening and genotyping
Mice were maintained in 100% C57BL/6N background. All mouse studies were
conducted in compliance with an Institutional Animal Care and Use Committee protocol.
Live mice were weaned at the age of three weeks, and ear biopsies were collected. The
tissues were digested by Lysis buffer (1X PCR buffer, 1% Triton X, 250µg/uL Proteinase
K) at 550C overnight, and heated at 950C for 15 minutes to denature Proteinase K. 2µL
of the lysed tissue extract was used for PCR reaction to amplify 1Kb region of the
targeted site or selected off-target sites. The PCR product is gel purified and sangersequenced to identify any indels at the target site.
Screening primer Fwd: CGCATGCGTAGACACGCCTATG
Screening primer Rev: GCACAAGGGCAGAGATGATCAG
Diexf∆26 Genotyping primer Fwd: CGTTTCCGCTATGGGCAAACG
Diexf∆26 Genotyping primer Rev: CTCAACTCGGCCGGAACCAG
sgRNA1 OTS1 Fwd: CCTCCACCCCGCTCTAATTTC
sgRNA1 OTS1 Rev: CTGCCCTTCTCCTCTGTGGATC
sgRNA1 OTS2 Fwd: GGGAAGGAAGCTCAGGGGTTAG
sgRNA1 OTS2 Rev: CCACCTTGGAATTCCGTTCTTTC
sgRNA1 OTS3 Fwd: GGAGGCAGTGAAAGATAAAG
sgRNA1 OTS3 Rev: CGGATCACTCAGTTTGAATC
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sgRNA1 OTS4 Fwd: CGGGTTGCTTTGGAAAAAATACAC
sgRNA1 OTS4 Rev: CGGGCTGACCGTATTGAGGGAATC
sgRNA2 OTS1 Fwd: GGCTGTGGTAGGTGATTAC
sgRNA2 OTS1 Rev: GGTCACCAGCTAAGGAATG
sgRNA2 OTS2 Fwd: GACCCGGGTAAGAAGAAAAAG
sgRNA2 OTS2 Rev: CGGCGAAACAGACTGTTTC
sgRNA2 OTS3 Fwd: CACACAGGATGTCACATTCC
sgRNA2 OTS3 Rev: GCGAGCTGCCCTTTTAAG
sgRNA2 OTS4 Fwd: GCCATGCAACCTCCTAAG
sgRNA2 OTS4 Rev: CTCCAGGATCTTGCTTTTGG
sgRNA2 OTS5 Fwd: CTGGGACTAGTTTCTGGACTC
sgRNA2 OTS5 Rev: GCACACCCTGTATCTAACATTG
sgRNA2 OTS6 Fwd: GGGGCAGAGACAATCATG
sgRNA2 OTS6 Rev: GGCTGAGAATGGCTCAAG
E7.5 and E9.5 embryo dissection
Heterozygous animals were mated with each other, and plugs were examined
every morning. Females positive for plug (E0.5) were euthanized 7 days (E7.5) or 9
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days (E9.5) from that date. Uteri were dissected, and each conceptus is separated and
dissected. Embryos from each conceptus were collected and genotyped.
Blastocyst Harvest and Genotyping
8-12-week-old female mice were super-ovulated by intra-peritoneal injection of 5
IU of PMSG and 5 IU of HCG 48 hours later, and set up in an individual mating cage
with a male. Plugged females were euthanized 3 days later (E3.5), and their uteri
harvested. Buffer was injected into each uterine horn to flush out the blastocysts.
Blastocyst were transferred into 96-well-plate, lysed, denatured, and genotyped.
Irradiation of Mice
6-9 week old mice were exposed to one dose of 6 Gy IR in a cesium-137
irradiator and monitored daily for four weeks. Moribund animals were sacrificed.
Western Blot
Protein lysates were prepared by lysing tissues in NP-40 buffer. Protein
estimation was carried out with BCA (Protein Assay kit, Pierce). 100ug of lysate were
resolved on 8% SDS-PAGE and immunoblotted with antibodies against Diexf (1:500;
A305-122A, BETHYL) and Vinculin (1:1000; V9131, Sigma).
Statistical analysis
Student's t-tests and Kaplan-Meier survival analyses were performed using Prism
5 software (GraphPad Software). P-values <0.05 were considered statistically
significant.
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Results
Diexf is amplified in human cancers with an inverse correlation to p53 alterations
Diexf is an evolutionarily conserved gene from yeast to humans, and recent
studies in zebrafish have suggested that the Diexf protein is a negative regulator of p53
(Chen et al., 2005; Tao et al., 2013). In many different human cancers with wild type
TP53, other p53 inhibitors such as MDM2 and MDM4 are frequently amplified or
overexpressed (Pant et al., 2017; Wasylishen and Lozano, 2016). To ascribe a role of
Diexf in human cancers, we exploited the data from cBioPortal and examined whether a
similar inverse correlation between TP53 and DIEXF exists (Cerami et al., 2012; Gao et
al., 2013). We observed that DIEXF is indeed amplified in many human cancers (Figure
21A) including >10% of the breast cancers, neuroendocrine prostate cancers (NEPCs),
and cholangiosarcomas. In a breast cancer dataset of 2051 cases (Pereira et al., 2016),
36% of total cases (n=734) had TP53 alterations and 25% (n=513) had Diexf
amplification, but only 6% (n=134) had both (Figure 21B). A significant mutual
exclusivity (P<0.001) was present between DIEXF amplification and TP53 alterations.
Significant mutual exclusivity was also observed in other breast cancer datasets in
Figure 1A. These results support the hypothesis that DIEXF is a negative regulator of
the p53 pathway. However, it is important to note that DIEXF is located on chromosome
1q in close proximity (5.3Mbp) to the MDM4 locus. It is thus possible that DIEXF
amplification is a consequence of co-amplification with MDM4. When we analyzed the
same breast cancer datasets, we observed that amplification of DIEXF and MDM4
significantly overlapped (P<0.001, Figure 21C). Similarly, when we examined other
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tumor types with DIEXF amplification, we found significant overlap with MDM4
amplification. We did not find any cancer where DIEXF amplification was significantly
higher than MDM4 amplification. However, cases where either MDM4 or DIEXF
amplification occurred independent of each other were also present in all tumor types
examined.
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Figure 21: DIEXF Amplification in Human Cancers. A. Human cancer datasets
from cBioPortal showing DIEXF alterations in human cancers. B. A breast cancer
dataset (METABRIC) of 2051 patients shows DIEXF amplification and TP53
alterations. There is a significant inverse correlation between DIEXF amplification
and TP53 alterations (P<0.001). Only cases with alteration in queried gene are
shown. C. A breast Cancer dataset (METABRIC) of 2051 patients shows DIEXF and
MDM4 co-amplifications. Only cases with amplification of at least one gene is shown.
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Generation of Diexf knock-out mice
To directly evaluate the function of Diexf and its potential role in regulation of the
p53 pathway in vivo, I generated a Diexf deletion in mice using CRISPR/Cas9
technology. Diexf is a 26 Kbp gene with 12 exons that code for a 772 amino acid protein
(89 KDa) in mice. Exon1 is 229 base pairs and contains the translational start site. I
selected two sequences in exon1 downstream of the start codon to target with specific
sgRNAs and the spCas9 endonuclease (Fig. 22A). The two target sequences are
located at the translational start site (bases 123-142) and further downstream (bases
188-207). Both sgRNAs had very few possible off-target sites with scores of 98 and 93
out of 100 respectively per crispr.mit.edu analysis tool. When both sgRNAs and spCas9
endonuclease were used, only mice with disruption of the Diexf alleles at site 2 were
obtained. Multiple alleles with both in-frame and frame-shift mutations were generated
(Fig. 22B). Of 16 animals born, 14 had alterations in one or both alleles of the Diexf
gene (Table 7). Even though both alleles were targeted in 6 mice, no mice were born
with two frame-shift alleles suggesting that homozygous loss may be lethal (Table 7). I
selected two alleles with frame shift mutations for further experiments. The first allele
Diexf∆26 had 26 base pairs deleted (bases 194-219 in exon 1) resulting in a premature
stop signal after 85 amino acids (23 endogenous and 62 novel amino acids). The
second allele Diexf13ins had a 13 base pair insertion between bases 200-201 in exon 1
resulting in premature stop after 28 amino acids (26 endogenous and 2 novel amino
acids).
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To rule out the possibility of unintended mutations being incorporated into the
genome by the CRISPR/Cas9 system, I evaluated off-target cleavage at the top six
sites for sgRNA2 and top four sites for sgRNA1 based on scoring by crispr.mit.edu
analysis tool (Tables 8-9). I did not observe any off-target mutations in these mice.
Diexf∆26 and Diexf13ins mice were crossed with wild type animals for three generations to
further mitigate the potential of any off-target mutation being carried over to the
experimental cohort.

111

Figure 22: Diexf Targeting Using CRISPR/Cas9 System A. Genomic map of Diexf
gene with 12 exons highlighting the sequence of exon 1 with the two target sites.
The size of exons and introns are proportional to their width in the map. Translational
start site (start codon) is in red, target sequence is underlined, and Protospacer
adjacent motif (PAM) sequence is in blue. B. Details of all alleles generated with
alterations. Target site 2 is in blue cells, and alterations (deletion [-] or insertion) are
in red. I.F., in-frame mutation; F.S., frame-shift mutation; *, an additional 12 base
deletion (not shown) in this allele is 156 bases downstream of the 3 base insertion
site.
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Table 7: Genotype of Diexf alleles in all mice generated by CRISPR/Cas9 targeting

Genotype
Mouse #

Allele 1

Allele 2

1

13ins

∆9

2

∆26

∆9

3

∆26

WT

4*

3ins∆12

∆9 (b) and ∆26

5*

∆2

4ins∆16 and ∆9

6

∆3∆6

8ins∆6

7

∆9

∆9

8*

∆9

∆3 and WT

9*

∆9

8ins∆17 and WT

10-14 (n=5)

∆9

WT

15-16 (n=2)

WT

WT

*, Mosaics.
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Table 8: List of On- and off-target sites for Diexf sgRNA1
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Table 9: List of On- and off-target sites for Diexf sgRNA2
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Diexf null embryos are peri-implantation lethal
The two selected lines of Diexf knock-out alleles with frame-shift truncating
mutations were used to evaluate if homozygous null animals were viable. For each line,
I inter-crossed heterozygous animals and genotyped progeny at the time of weaning. Of
22 pups born from 3 litters in Diexf13ins line, 7 animals were wild type, 15 were
heterozygous mutants, and no animals were homozygous mutants (Table 2). Similarly,
of 48 pups born from 7 litters in the Diexf∆26 line; 19 animals were wild type, 29 were
heterozygous, and none were homozygous mutants (Table 2). The deviations from the
expected Mendelian ratios were significant in both lines (p=0.0001 and p=0.02
respectively). Failure to generate any viable homozygous knock-out animals clearly
demonstrates an essential role of Diexf during embryonic development in mice.
In order to determine the timing of the lethality of homozygous mutants, I
harvested and genotyped the embryos from Diexf+/∆26 heterozygous crosses at various
developmental time points (Table 10). I screened 13 embryos from 2 females at E14.5
and did not find any homozygous mutants. At E9.5, I screened 18 embryos from 3
females and observed 4 wild type, 10 heterozygous mutant embryos, and 4 empty
conceptus. Similarly, of 30 embryos from 4 females at E7.5, I observed 6 empty
conceptus while the remaining embryos were either wild type (n=9) or heterozygous
mutants (n=15). The finding of empty conceptus demonstrated that mutant embryos
implanted but died soon thereafter and were likely resorbed by E7.5 (Papaioannou and
Behringer, 2012). This clearly demonstrates that the Diexf null embryos are periimplantation lethal at E4.5-E5.5 stages. To further evaluate the viability of mutant
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embryos at pre-implantation stage, I flushed out blastocysts from heterozygous crosses,
observed the morphology under microscope, and genotyped them. I did not observe
obvious defects in dozens of blastocysts examined, and genotyping of 8 random
blastocysts confirmed presence of homozygous mutants (Figure 23). Combined, these
results establish Diexf as an essential gene for early embryonic development.
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Table 10: Homozygous deletion of Diexf is embryonic lethal at peri-implantation
stage (E4.5-E5.5) in mice

Diexf+/- X Diexf+/- : Observed (Expected)
Allele
Age
Diexf+/+

Diexf+/-

Diexf-/-

Empty Conceptus

Diexf13ins

P21

7 (6)

15 (11)

0 (6)

-

Diexf∆26

P21

19 (12)

29 (24)

0 (12)

-

Diexf∆26

E14.5

4 (3)

9 (7)

0 (3)

0

Diexf∆26

E9.5

4 (4)

10 (7)

0 (4)

4

∆26

E7.5

9 (6)

15 (12)

0 (6)

6

Diexf
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Figure 23: Genotyping of blastocysts. Agarose gel electrophoresis of PCR
products from blastocyst DNA showing wild type band (165bp) and mutant band
(139bp). Lanes 2 and 3 show a single mutant band indicating Diexf∆26/∆26 blastocysts.
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Embryonic lethality of Diexf-/- mice is p53-independent
Early embryonic lethality occurs in knock-out mouse models of the p53 inhibitors
Mdm2 and Mdm4. Lethality in these models is p53-dependent as the phenotype is
rescued upon concomitant deletion of p53. Studies in zebrafish suggest that Diexf is a
potential negative regulator of p53, and embryonic lethality of Def-null fish is partially
p53-dependent. In order to address if embryonic lethality of Diexf-null mice is also p53dependent, I crossed heterozygous animals carrying the Diexf∆26 null allele with p53-/mice. The resulting Diexf+/∆26; p53+/- double heterozygous mice were inter-crossed and
progeny were genotyped at weaning. I screened 108 animals from 15 litters and
observed no Diexf∆26/∆26 homozygous mutants irrespective of p53 status (Table 11). Of
the 16 mice with p53-/- genotype, 3 were wild type and 13 were heterozygous for
Diexf∆26. These results clearly demonstrate that loss of p53 fails to rescue the
embryonic lethality due to homozygous Diexf loss. To evaluate the possibility of a partial
rescue (delayed lethality) upon p53 loss in Diexf-null embryos, I also screened embryos
from Diexf+/∆26; p53+/- double heterozygous mice crossed with Diexf+/∆26; p53-/- animals
at various time points. I failed to find any embryos with the Diexf∆26/∆26 genotype
irrespective of p53 status at the time points examined, and empty conceptus were
observed at E7.5 and E9.5 as previously observed with the Diexf+/∆26 heterozygous
crosses (Table 11). These results indicate that embryonic lethality in mice due to Diexf
loss is not a result of inappropriate activation of the p53 pathway.
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Table 11: Loss of p53 fails to rescue the embryonic lethality in Diexf-null mice

Diexf+/∆26; p53+/- X Diexf+/∆26; p53+/- : Observed (Expected)

Age

P21

Diexf+/+

Diexf+/+

Diexf+/+

Diexf+/-

Diexf+/-

Diexf+/-

Diexf-/-

Diexf-/-

Diexf-/-

P53+/+

P53+/-

P53-/-

p53+/+

p53+/-

p53-/-

P53+/+

P53+/-

P53-/-

7 (7)

26 (14)

3 (7)

20 (14)

38 (27)

14 (14)

0 (7)

0 (14)

0 (7)

Diexf+/∆26; p53-/- X Diexf+/∆26; p53+/- : Observed (Expected)

Diexf+/+

Diexf+/+

Diexf+/-

Diexf+/-

Diexf-/-

Diexf-/-

Empty

P53-/+

P53-/-

p53+/-

p53-/-

P53+/-

P53-/-

Conceptus

E17.5 3 (2)

1 (2)

6 (4)

4 (4)

0 (2)

0 (2)

0

E9.5

3 (3)

3 (3)

9 (6)

8 (6)

0 (3)

0 (3)

5

E7.5

3 (2)

0 (2)

6 (4)

7 (4)

0 (2)

0 (2)

4

Age

Top. Inter-cross between Diexf+/∆26; p53+/- double heterozygous animals and observed
vs expected numbers for all genotypes.
Bottom. Observed vs expected numbers for all genotypes in embryos derived from
Diexf+/∆26; p53+/- mice crossed with Diexf+/∆26; p53-/- mice. All expected numbers are
rounded to the nearest integer.
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Diexf heterozygous animals are resistant to 6Gy ionizing radiation
I next wanted to explore the possibility that Diexf has different functions during
development and in adult animals. To test whether Diexf is expressed in adults, I first
examined Diexf protein expression in various tissues of 8-week-old wild type mice by
immunoblotting. I observed that Diexf was expressed in all mouse tissues that I
examined, with high expression in the digestive organs and low expression in the heart
(Figure 24A). Next, I wanted to evaluate the role of Diexf in p53 regulation under stress
condition. p53 is stabilized and activated after exposure to stress conditions such as
DNA damage (Pant and Lozano, 2014). Previous studies have shown that
heterozygosity of Mdm2 and Mdm4 results in sensitivity to sub-lethal ionizing radiation
(IR) in a p53-dependent manner (Terzian et al., 2007). To evaluate if Diexf regulates
p53 activity in the adult mouse in response to DNA damage, I irradiated 5-9 week old
Diexf+/∆26 heterozygous animals (n=14) along with Mdm2P2/P2 animals (n=5) as a
positive control (Pant et al., 2013), and wild type animals (n=12) as a negative control.
Mice were irradiated with sub-lethal IR (one dose of 6 Gy) and monitored daily for four
weeks. As expected, radio-sensitive MdmP2/P2 animals died within three weeks after
irradiation (Figure 24B). However, both Diexf heterozygous and wild-type mice survived
the sub-lethal 6 Gy IR exposure and were alive by the end of 4 weeks monitoring period
(Figure 24B). These results demonstrate that Diexf is not a potent negative regulator of
p53 following DNA damage in adult mice.
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Figure 24: Diexf heterozygous animals are not sensitive to sub-lethal ionizing
irradiation. A. Western blot showing Diexf expression in different mouse tissues.
Vinculin was used to evaluate protein loading. SI, Small intestine; LI, Large Intestine;
St, Stomach; Li, Liver; Br, Brain; Sp, Spleen; Th, Thymus; He, Heart; Lu, Lung; Ki,
Kidney; Te, Testes. B. Survival curve of Diexf+/∆26 animals after 6 Gy irradiation. Wild
type and MdmP2/P2 animals were used as negative and positive controls respectively.

123

Discussion
Understanding the mechanisms regulating the p53 pathway has important
implications in cancer. MDM2 and MDM4 are critical p53 inhibitors whose genetic loci
are amplified in several tumor types that retain wild-type p53. This knowledge has
spurred the development of MDM2 inhibitors for cancer therapeutics. Recently, a novel
gene Diexf was found to regulate the expression of a specific p53 isoform in zebrafish,
and p53 loss was able to partially rescue the developmental defects in the mutant
zebrafish digestive system. These data suggested a potential role of Diexf in regulating
the p53 pathway in mammals.
Recent studies show that Diexf homologs in S. cerevisiae (Utp25p) and A.
thaliana (Nof1) are nucleolus-localized components of small subunit processome that
regulate pre-rRNA processing (Charette and Baserga, 2010; Goldfeder and Oliveira,
2010; Harscoet et al., 2010). In addition to this function, Def also negatively regulates
p53 activity in zebrafish via proteasome-independent degradation of p53 protein in the
nucleolus (Nuaaman and Benchimol, 2013; Tao et al., 2013; Tao et al., 2017). Here, I
first highlighted a significant mutually exclusive relationship between DIEXF
amplification and TP53 mutation in human breast cancers. This relationship must,
however, be considered in the context of the DIEXF genomic locus. DIEXF is in close
proximity to MDM4 gene which encodes a potent p53-inhibitor that is frequently
amplified in human cancers (Danovi et al., 2004; Riemenschneider et al., 2003). Given
the data presented herein, it is likely that this mutually exclusive relationship between
DIEXF and TP53 is driven by amplification of MDM4. I cannot, however, exclude the
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possibility that overexpression of DIEXF contributes to p53 pathway attenuation in these
cancers.
To directly evaluate the role of Diexf as a regulator of the p53 pathway in
mammals, I used CRISPR/Cas9 technology to generate multiple independent Diexf
knockout alleles in the mouse. The CRISPR/Cas9 system has revolutionized the way
we generate animal models as it is efficient, fast, and less expensive than traditional
techniques. One limitation of this system, however, is the difficulty in generation of
knock-out alleles of genes that may be essential. If both alleles of an essential gene are
disrupted, the embryos may not survive. Using only sgRNA1 and spCas9
endonuclease, I failed to generate any mice with disruption of Diexf gene. We could not
determine whether the sgRNA failed to target the gene or if the sgRNA was so efficient
that bi-allelic disruption of the gene in all targeted mice led to lethality. When both
sgRNA1 and sgRNA2 were co-injected, only sgRNA2 generated mutations at its target
site indicating that sgRNA1 failed. Moreover, even though both alleles were targeted by
sgRNA2 in many animals, one or both alleles were always in-frame resulting in embryo
survival. If most mutations had not been in-frame, more embryos would have died. We
observed the same 9 bp deletion in 10/16 mice. The observation that non-homologous
end joining (NHEJ) based repair can result in frequent recurrence of the same mutation
in targeted alleles also presents a problem. If the recurring mutation is frame-shift, then
more embryos would die. On the other hand, if the recurring mutation is in-frame, the
possibility of getting a knock-out allele is diminished. Therefore, both lethality and
sgRNA failure should be considered while targeting a possible essential gene. Another
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major concern of the CRISPR/Cas9 system is the modifications (insertions or deletions)
at off-target sites. To my knowledge, there has been no report of high frequency
targeting at non-targeted sites with 2 or more mismatches in mouse models. When I
screened the top four and the top six predicted off-target sites for sgRNA1 and sgRNA2
respectively, I did not find any mutations.
Using two independent null-alleles, I demonstrate that homozygous loss of Diexf
is peri-implantation lethal, establishing Diexf as an essential developmental gene in the
mouse. My observation that Diexf-null mouse embryos are peri-implantation lethal is
very different from the phenotype observed in zebrafish. In fish, the lethality occurs due
to digestive organ failure, while in mice, the embryos died before any of the digestive
organs developed. In addition, the abnormalities in mutant fish are p53-dependent, as
the phenotype can be partially rescued by concomitant p53 loss. However, embryonic
lethality in mice due to Diexf loss was not rescued or even delayed by loss of p53
demonstrating that the phenotype is not a consequence of inappropriate activation of
p53. The role of p53 regulators such as Mdm4 seem to have evolved from fish to
mammals as well. A recent study has shown that Mdm4 is dispensable in zebrafish,
while it is essential for murine embryonic development [4, 5, 7, 25]. We could
hypothesize that as the role of Mdm4 to inhibit p53 became more potent in mammals,
the role of other p53 regulators such as Diexf have diminished. I cannot rule out the
possibility that Diexf may cooperate with other p53 regulators to attenuate the p53
pathway, but we can conclude that it does not have an essential role in p53 regulation
on its own.
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Finally, I find no evidence of Diexf as a significant functional regulator of the p53
pathway in response to ionizing radiation. Heterozygous loss of well-established p53
regulators results in sensitivity to a sub-lethal dose of ionizing radiation (Terzian et al.,
2007). Diexf heterozygous animals do not exhibit enhanced radio-sensitivity, further
supporting the argument that Diexf is not a potent inhibitor of the p53 pathway in mice
under these conditions. In human cancers, negative regulators of the p53 pathway are
frequently overexpressed, so it remains possible that the overexpression of DIEXF may
impact the p53 pathway and have pathological consequences. Moreover, it may inhibit
p53 function under certain conditions that we have not tested.
Combined, this work identifies Diexf as an essential developmental gene in the
mouse, and suggests that the function(s) of Diexf are largely independent of a role as a
negative regulator of p53. It has been clearly demonstrated that Def is a component of
the ribosomal processome, and the Def-Capn3 pathway possibly regulates proteins
other than p53 in the nucleolus. Two previous publications with Capn3 deletion in mice
show that the Capn3-/- mice are viable and fertile, and their digestive organs are not
affected (Kramerova et al., 2004; Richard et al., 2000). These results indicate that
embryonic lethality in Diexf-null mice is independent of both p53 and Calpain3, and
suggests that the role of Diexf has evolved to have very diverse functions. Moreover, as
DIEXF amplifications occur in cancers, future studies to better understand its functions
will be instructive and important.
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